

AGREED MINUTES ON THE
AGREEMENT ON MUTUAL RECOGNITION
BETWEEN THE UNITED STATES OF AMERICA AND
THE EUROPEAN COMMUNITY

This is to reflect our understanding that the attached Agreement on Mutual Recognition between the United States of America and the European Community represents the text we commit to submit to our respective authorities with a view to completing the necessary procedures for approval and implementation.

For the United States of America

Charles...
2/20/97

For the European Community

Leon B...

20 June 1997

**AGREEMENT ON MUTUAL RECOGNITION
BETWEEN THE UNITED STATES OF AMERICA AND
THE EUROPEAN COMMUNITY**

TABLE OF CONTENTS

1.	Framework	Page 1
2.	Telecommunication Equipment	Page 16
3.	Electromagnetic Compatibility (EMC)	Page 29
4.	Electrical Safety	Page 40
5.	Recreational Craft	Page 49
6.	Pharmaceutical Good Manufacturing Practice (GMP)	Page 54
7.	Medical Devices	Page 78

Noting that this Agreement is not intended to displace private sector bilateral and multilateral arrangements among conformity assessment bodies or to affect regulatory regimes allowing for manufacturers' self-assessments and declarations of conformity.

Bearing in mind that the Agreement on Technical Barriers to Trade, an agreement annexed to the Agreement establishing the World Trade Organization (WTO), imposes obligations on the Parties as Contracting Parties to the WTO, and encourages such Contracting Parties to enter into negotiations for the conclusion of agreements for the mutual recognition of results of each other's conformity assessment;

Recognizing that any such mutual recognition needs to offer an assurance of conformity with applicable technical regulations or standards equivalent to the assurance offered by the Party's own procedures;

Recognizing the need to conclude an Agreement on Mutual Recognition (MRA) in the field of conformity assessment with sectoral annexes; and

Bearing in mind the respective commitments of the Parties under bilateral, regional and multilateral environment, health, safety and consumer protection agreements.

Have agreed as follows:

Article 1

DEFINITIONS

1. The following terms and definitions shall apply to this Agreement only:
 - ***Designating Authority*** means a body with power to designate, monitor, suspend, remove suspension of, or withdraw conformity assessment bodies as specified under this Agreement.
 - ***Designation*** means the identification by a Designating Authority of a conformity assessment body to perform conformity assessment procedures under this Agreement.
 - ***Regulatory Authority*** means a government agency or entity that exercises a legal right to control the use or sale of products within a Party's jurisdiction and may take enforcement action to ensure that products marketed within its jurisdiction comply with legal requirements.
2. Other terms concerning conformity assessment used in this Agreement shall have the meaning given elsewhere in this Agreement or in the definitions contained in Guide 2 (1996 edition) of the International Organization for Standardization (ISO) and the

AGREEMENT ON MUTUAL RECOGNITION
BETWEEN THE UNITED STATES OF AMERICA AND
THE EUROPEAN COMMUNITY

The Government of the United States of America and the European Community, hereinafter referred to as "the Parties",

Considering the traditional links of friendship that exist between the United States of America (U.S.) and the European Community (EC);

Desiring to facilitate bilateral trade between them;

Recognizing that mutual recognition of conformity assessment activities is an important means of enhancing market access between the Parties;

Recognizing that an agreement providing for mutual recognition of conformity assessment activities is of particular interest to small and medium-sized businesses in the U.S. and the EC;

Recognizing that any such mutual recognition also requires confidence in the continued reliability of the other Party's conformity assessments;

Recognizing the importance of maintaining each Party's high levels of health, safety, environmental and consumer protection;

Recognizing that mutual recognition agreements can positively contribute in encouraging greater international harmonization of standards;

Article 4

GENERAL COVERAGE OF THE AGREEMENT

1. This Agreement applies to conformity assessment procedures for products and/or processes and to other related cooperative activities as described in this Agreement.
2. Sectoral Annexes may include:
 - a) a description of the relevant legislative, regulatory and administrative provisions pertaining to the conformity assessment procedures and technical regulations;
 - b) a statement on the product scope and coverage;
 - c) a list of Designating Authorities;
 - d) a list of agreed conformity assessment bodies or authorities or a source from which to obtain a list of such bodies or authorities and a statement of the scope of the conformity assessment procedures for which each has been agreed;
 - e) the procedures and criteria for designating the conformity assessment bodies;
 - f) a description of the mutual recognition obligations;
 - g) a sectoral transition arrangement;
 - h) the identity of a sectoral contact point in each Party's territory; and
 - i) a statement regarding the establishment of a Joint Sectoral Committee.
3. This Agreement shall not be construed to entail mutual acceptance of standards or technical regulations of the Parties and, unless otherwise specified in a Sectoral Annex, shall not entail the mutual recognition of the equivalence of standards or technical regulations.

Article 5

TRANSITIONAL ARRANGEMENTS

The Parties agree to implement the transitional commitments on confidence building as specified in the Sectoral Annexes.

International Electrotechnical Commission (IEC). In the event of an inconsistency between ISO/IEC Guide 2 and definitions in this Agreement, the definitions in this Agreement shall prevail.

Article 2

PURPOSE OF THE AGREEMENT

This Agreement specifies the conditions by which each Party will accept or recognize results of conformity assessment procedures, produced by the other Party's conformity assessment bodies or authorities, in assessing conformity to the importing Party's requirements, as specified on a sector-specific basis in the Sectoral Annexes, and to provide for other related cooperative activities. The objective of such mutual recognition is to provide effective market access throughout the territories of the Parties with regard to conformity assessment for all products covered under this Agreement. If any obstacles to such access arise, consultations will promptly be held. In the absence of a satisfactory outcome of such consultations, the Party alleging its market access has been denied, may, within 90 days of such consultation, invoke its right to terminate the Agreement in accordance with Article 21.

Article 3

GENERAL OBLIGATIONS

1. The United States shall, as specified in the Sectoral Annexes, accept or recognize results of specified procedures, used in assessing conformity to specified legislative, regulatory, and administrative provisions of the United States, produced by the other Party's conformity assessment bodies and/or authorities.
2. The European Community and its Member States shall, as specified in the Sectoral Annexes, accept or recognize results of specified procedures, used in assessing conformity to specified legislative, regulatory and administrative provisions of the European Community and its Member States, produced by the other Party's conformity assessment bodies and/or authorities.
3. Where sectoral transition arrangements have been specified in Sectoral Annexes, the above obligations will apply following the successful completion of those sectoral transition arrangements, with the understanding that the conformity assessment procedures utilized assure conformity to the satisfaction of the receiving Party, with applicable legislative, regulatory and administrative provisions of that Party, equivalent to the assurance offered by the receiving Party's own procedures.

technical competence or compliance of a proposed conformity assessment body, or indicates in writing that it requires an additional 30 days to more fully verify such evidence, such conformity assessment body shall not be included on the list of conformity assessment bodies in the applicable Sectoral Annex. In this instance, the Joint Committee may decide that the body concerned be verified. After the completion of such verification, the proposal to list the conformity assessment body in the Sectoral Annex may be resubmitted to the other Party.

Article 8

SUSPENSION OF LISTED CONFORMITY ASSESSMENT BODIES

The following procedures shall apply with regard to the suspension of a conformity assessment body listed in a Sectoral Annex:

- a) A Party shall notify the other Party of its contestation of the technical competence or compliance of a conformity assessment body listed in a Sectoral Annex and the contesting Party's intent to suspend such conformity assessment body. Such contestation shall be exercised when justified in an objective and reasoned manner in writing to the other Party;
- b) The conformity assessment body shall be given prompt notice by the other Party and an opportunity to present information in order to refute the contestation or to correct the deficiencies which form the basis of the contestation;
- c) Any such contestation shall be discussed between the Parties in the relevant Joint Sectoral Committee. If there is no Joint Sectoral Committee, the contesting Party shall refer the matter directly to the Joint Committee. If agreement to suspend is reached by the Joint Sectoral Committee or, if there is no Joint Sectoral Committee, by the Joint Committee, the conformity assessment body shall be suspended;
- d) Where the Joint Sectoral Committee or Joint Committee decides that verification of technical competence or compliance is required, it shall normally be carried out in a timely manner by the Party in whose territory the body in question is located, but may be carried out jointly by the Parties in justified cases;
- e) If the matter has not been resolved by the Joint Sectoral Committee within 10 days of the notice of contestation, the matter shall be referred to the Joint Committee for a decision. If there is no Joint Sectoral Committee, the matter shall be referred directly to the Joint Committee. If no decision is reached by the Joint Committee within 10 days of the referral to it, the conformity assessment body shall be suspended upon the request of the contesting Party;

1. The Parties agree that each sectoral transitional arrangement shall specify a time period for completion.
2. The Parties may amend any transitional arrangement by mutual agreement.
3. Passage from the transitional phase to the operational phase shall proceed as specified in each Sectoral Annex, unless either Party documents that the conditions provided in such Sectoral Annex for a successful transition are not met.

Article 6

DESIGNATING AUTHORITIES

The Parties shall ensure that the Designating Authorities specified in the Sectoral Annexes have the power and competence in their respective territories to carry out decisions under this Agreement to designate, monitor, suspend, remove suspension of, or withdraw conformity assessment bodies.

Article 7

DESIGNATION AND LISTING PROCEDURES

The following procedures shall apply with regard to the designation of conformity assessment bodies and the inclusion of such bodies in the list of conformity assessment bodies in a Sectoral Annex:

- a) The Designating Authority identified in a Sectoral Annex shall designate conformity assessment bodies in accordance with the procedures and criteria set forth in that Sectoral Annex;
- b) A Party proposing to add a conformity assessment body to the list of such bodies in a Sectoral Annex shall forward its proposal of one or more designated conformity assessment bodies in writing to the other Party with a view to a decision by the Joint Committee;
- c) Within 60 days following receipt of the proposal, the other Party shall indicate its position regarding either its confirmation or its opposition. Upon confirmation, the inclusion in the Sectoral Annex of the proposed conformity assessment body or bodies shall take effect; and
- d) In the event that the other Party contests on the basis of documented evidence the

- e) Subsequent to the withdrawal of a conformity assessment body listed in a Sectoral Annex, a Party shall continue to accept the results of conformity assessment procedures performed by that conformity assessment body prior to withdrawal, unless a Regulatory Authority of the Party decides otherwise based on health, safety and environmental considerations or failure to satisfy other requirements within the scope of the applicable Sectoral Annex.

Article 10

MONITORING OF CONFORMITY ASSESSMENT BODIES

The following shall apply with regard to the monitoring of conformity assessment bodies listed in a Sectoral Annex:

- a) Designating Authorities shall assure that their conformity assessment bodies listed in a Sectoral Annex are capable and remain capable of properly assessing conformity of products or processes, as applicable, and as covered in the applicable Sectoral Annex. In this regard, Designating Authorities shall maintain, or cause to maintain, ongoing surveillance over their conformity assessment bodies by means of regular audit or assessment;
- b) The Parties undertake to compare methods used to verify that the conformity assessment bodies listed in the Sectoral Annexes comply with the relevant requirements of the Sectoral Annexes. Existing systems for the evaluation of conformity assessment bodies may be used as part of such comparison procedures;
- c) Designating Authorities shall consult as necessary with their counterparts, to ensure the maintenance of confidence in conformity assessment procedures. With the consent of both Parties, this consultation may include joint participation in audits/inspections related to conformity assessment activities or other assessments of conformity assessment bodies listed in a Sectoral Annex; and
- d) Designating Authorities shall consult, as necessary, with the relevant Regulatory Authorities of the other Party to ensure that all technical requirements are identified and are satisfactorily addressed.

- f) Upon the suspension of a conformity assessment body listed in a Sectoral Annex, a Party is no longer obligated to accept or recognize the results of conformity assessment procedures performed by that conformity assessment body subsequent to suspension. A Party shall continue to accept the results of conformity assessment procedures performed by that conformity assessment body prior to suspension, unless a Regulatory Authority of the Party decides otherwise based on health, safety or environmental considerations or failure to satisfy other requirements within the scope of the applicable Sectoral Annex; and
- g) The suspension shall remain in effect until agreement has been reached by the Parties upon the future status of that body.

Article 9

WITHDRAWAL OF LISTED CONFORMITY ASSESSMENT BODIES

The following procedures shall apply with regard to the withdrawal from a Sectoral Annex of a conformity assessment body:

- a) A Party proposing to withdraw a conformity assessment body listed in a Sectoral Annex shall forward its proposal in writing to the other Party;
- b) Such conformity assessment body shall be promptly notified by the other Party and shall be provided a period of at least 30 days from receipt to provide information in order to refute or to correct the deficiencies which form the basis of the proposed withdrawal;
- c) Within 60 days following receipt of the proposal, the other Party shall indicate its position regarding either its confirmation or its opposition. Upon confirmation, the withdrawal from the list in the Sectoral Annex of the conformity assessment body shall take effect;
- d) In the event the other Party opposes the proposal to withdraw by supporting the technical competence and compliance of the conformity assessment body, the conformity assessment body shall not at that time be withdrawn from the list of conformity assessment bodies in the applicable Sectoral Annex. In this instance, the Joint Sectoral Committee or the Joint Committee may decide to carry out a joint verification of the body concerned. After the completion of such verification, the proposal for withdrawal of the conformity assessment body may be resubmitted to the other Party; and

Article 14

JOINT COMMITTEE OF THE PARTIES

1. The Parties hereby establish a Joint Committee consisting of representatives of each Party. The Joint Committee shall be responsible for the effective functioning of the Agreement.
2. The Joint Committee may establish Joint Sectoral Committees comprised of appropriate Regulatory Authorities and others deemed necessary.
3. Each Party shall have one vote in the Joint Committee. The Joint Committee shall make its decisions by unanimous consent. The Joint Committee shall determine its own rules and procedures.
4. The Joint Committee may consider any matter relating to the effective functioning of this Agreement. In particular it shall be responsible for:
 - a) listing, suspension, withdrawal and verification of conformity assessment bodies in accordance with this Agreement;
 - b) amending transitional arrangements in Sectoral Annexes;
 - c) resolving any questions relating to the application of this Agreement and its Sectoral Annexes not otherwise resolved in the respective Joint Sectoral Committees;
 - d) providing a forum for discussion of issues that may arise concerning the implementation of this Agreement;
 - e) considering ways to enhance the operation of this Agreement;
 - f) coordinating the negotiation of additional Sectoral Annexes; and
 - g) considering whether to amend this Agreement or its Sectoral Annexes in accordance with Article 21.
5. When a Party introduces new or additional conformity assessment procedures affecting a Sectoral Annex, the Parties shall discuss the matter in the Joint Committee with a view to bringing such new or additional procedures within the scope of this Agreement and the relevant Sectoral Annex.

Article 11

CONFORMITY ASSESSMENT BODIES

Each Party recognizes that the conformity assessment bodies listed in the Sectoral Annexes fulfill the conditions of eligibility to assess conformity in relation to its requirements as specified in the Sectoral Annexes. The Parties shall specify the scope of the conformity assessment procedures for which such bodies are listed.

Article 12

EXCHANGE OF INFORMATION

1. The Parties shall exchange information concerning the implementation of the legislative, regulatory, and administrative provisions identified in the Sectoral Annexes.
2. Each Party shall notify the other Party of legislative, regulatory and administrative changes related to the subject matter of this Agreement at least 60 days before their entry into force. Where considerations of safety, health or environmental protection require more urgent action, a Party shall notify the other Party as soon as practicable.
3. Each Party shall promptly notify the other Party of any changes to its Designating Authorities and/or conformity assessment bodies.
4. The Parties shall exchange information concerning the procedures used to ensure that the listed conformity assessment bodies under their responsibility comply with the legislative, regulatory, and administrative provisions outlined in the Sectoral Annexes.
5. Regulatory Authorities identified in the Sectoral Annexes shall consult as necessary with their counterparts, to ensure the maintenance of confidence in conformity assessment procedures and to ensure that all technical requirements are identified and are satisfactorily addressed.

Article 13

SECTORAL CONTACT POINTS

Each Party shall appoint and confirm in writing contact points to be responsible for activities under each Sectoral Annex.

Article 17
CONFIDENTIALITY

1. Each Party agrees to maintain, to the extent required under its laws, the confidentiality of information exchanged under this Agreement.
2. In particular, neither Party shall disclose to the public, nor permit a conformity assessment body to disclose to the public, information exchanged under this Agreement that constitutes trade secrets, confidential commercial or financial information, or information that relates to an ongoing investigation.
3. A Party or a conformity assessment body may, upon exchanging information with the other Party or with a conformity assessment body of the other Party, designate the portions of the information that it considers to be exempt from disclosure.
4. Each Party shall take all precautions reasonably necessary to protect information exchanged under this Agreement from unauthorized disclosure.

Article 18

FEES

Each Party shall endeavor to ensure that fees imposed for services under this Agreement shall be commensurate with the services provided. Each Party shall ensure that, for the sectors and conformity assessment procedures covered under this Agreement, it shall charge no fees with respect to conformity assessment services provided by the other Party.

Article 19

AGREEMENTS WITH OTHER COUNTRIES

Except where there is written agreement between the Parties, obligations contained in mutual recognition agreements concluded by either Party with a party not a signatory to this Agreement (a third party) shall have no force and effect with regard to the other Party in terms of acceptance of the results of conformity assessment procedures in the third party.

Article 20

TERRITORIAL APPLICATION

This Agreement shall apply, on the one hand, to the territories in which the Treaty establishing the European Community is applied, and under the conditions laid down in that Treaty and, on the other hand, to the territory of the United States.

Article 15

PRESERVATION OF REGULATORY AUTHORITY

1. Nothing in this Agreement shall be construed to limit the authority of a Party to determine, through its legislative, regulatory and administrative measures, the level of protection it considers appropriate for safety; for protection of human, animal, or plant life or health; for the environment; for consumers; and otherwise with regard to risks within the scope of the applicable Sectoral Annex.
2. Nothing in this Agreement shall be construed to limit the authority of a Regulatory Authority to take all appropriate and immediate measures whenever it ascertains that a product may: (a) compromise the health or safety of persons in its territory; (b) not meet the legislative, regulatory, or administrative provisions within the scope of the applicable Sectoral Annex; or (c) otherwise fail to satisfy a requirement within the scope of the applicable Sectoral Annex. Such measures may include withdrawing the products from the market, prohibiting their placement on the market, restricting their free movement, initiating a product recall, and preventing the recurrence of such problems, including through a prohibition on imports. If the Regulatory Authority takes such action, it shall inform its counterpart authority and the other Party within fifteen days of taking such action, providing its reasons.

Article 16

SUSPENSION OF RECOGNITION OBLIGATIONS

Either Party may suspend its obligations under a particular Sectoral Annex, in whole or in part, if:

- a) a Party suffers a loss of market access for the Party's products within the scope of the Sectoral Annex as a result of the failure of the other Party to fulfill its obligations under the Agreement;
- b) the adoption of new or additional conformity assessment requirements as referenced in Article 14(5) results in a loss of market access for the Party's products within the scope of the Sectoral Annex because conformity assessment bodies designated by the Party in order to meet such requirements have not been recognized by the Party implementing the requirements; or
- c) the other Party fails to maintain legal and regulatory authorities capable of implementing the provisions of this Agreement.

2. For a given product or sector, the provisions contained in the relevant Sectoral Annexes shall apply in the first place, and the provisions of this text in addition to those provisions. In the case of any inconsistency between the provisions of a Sectoral Annex and this text, the Sectoral Annex shall prevail, to the extent of that inconsistency.
3. This Agreement shall not affect the rights and obligations of the Parties under any other international agreement.
4. In the case of the Sectoral Annex on Medical Devices, the Parties shall review the status of such Annex at the end of three years from entry into force.

This Agreement and the Sectoral Annexes are drawn up in two originals in the Danish, Dutch, English, Finnish, French, German, Greek, Italian, Portuguese, Spanish and Swedish languages, each text being equally authentic. In the event of inconsistencies of interpretation, the English text shall be determinative.

DONE at ____ this ____ day of ____, 1997.

FOR THE GOVERNMENT OF THE
UNITED STATES OF AMERICA:

FOR THE EUROPEAN COMMUNITY:

Article 21

ENTRY INTO FORCE, AMENDMENT AND TERMINATION

1. This Agreement including its Sectoral Annexes on Telecommunications Equipment, Electromagnetic Compatibility, Electrical Safety, Recreational Craft, Pharmaceutical GMP Inspections, and Medical Devices shall enter into force on the first day of the second month following the date on which the Parties have exchanged letters confirming the completion of their respective procedures for the entry into force of this Agreement.
2. This Agreement including any Sectoral Annex may, through the Joint Committee, be amended in writing by the Parties. The Parties may add a Sectoral Annex upon the exchange of letters. Such Annex shall enter into force 30 days following the date on which the Parties have exchanged letters confirming the completion of their respective procedures for the entry into force of the Sectoral Annex.
3. Either Party may terminate this Agreement in its entirety or any individual Sectoral Annex thereof by giving the other Party six months notice in writing. In the case of termination of one or more Sectoral Annexes, the Parties will seek to achieve by consensus to amend this Agreement, with a view to preserving the remaining Sectoral Annexes, in accordance with the procedures in this Article. Failing such consensus, the Agreement shall terminate at the end of six months.
4. Following termination of the Agreement in its entirety or any individual Sectoral Annex thereof, a Party shall continue to accept the results of conformity assessment procedures performed by conformity assessment bodies under this Agreement prior to termination, unless a Regulatory Authority in the Party decides otherwise based on health, safety and environmental considerations or failure to satisfy other requirements within the scope of the applicable Sectoral Annex.

Article 22

FINAL PROVISIONS

1. The Sectoral Annexes referred to in Article 21.1, as well as any New Sectoral Annexes added pursuant to Article 21.2, shall form an integral part of this Agreement.

U.S. -EC MRA Telecommunication Equipment Annex

SECTION I

LEGISLATIVE, REGULATORY AND ADMINISTRATIVE PROVISIONS

EC	U.S.
<p>Council Directive 91/263/EEC, as supplemented by Council Directive 93/97/EEC and amended by Council Directive 93/68/EEC, and interpretation thereof;</p> <p>(The Parties recognize that the Handbook on the implementation of Directive 91/263/EEC (ADLNB and ACTE approved), provides useful guidelines for the implementation of conformity assessment procedures falling under this Directive.);</p> <p>Commission Decisions (CTRs) established under Council Directives 91/263/EEC and 93/97/EEC;</p> <p>The EC Member States' legislation and regulations in respect of :</p> <p>(a) non-harmonized analogue connection to the public telecommunications network*;</p> <p>(b) non-harmonized radio transmitters-for which there is a civilian equipment authorization requirement;</p> <p>* The EC agrees to seek authority to include non-harmonized digital connections;</p> <p>For electrical safety, see Electrical Safety Sectoral Annex to the Agreement;</p> <p>For electromagnetic compatibility aspects, see Electromagnetic Compatibility (EMC) Sectoral Annex to the Agreement.</p>	<p>Communication Act of 1934, as amended by the Telecommunication Act of 1996, (Title 47 of the United States Code),</p> <p>the U.S. regulatory and administrative provisions in respect of telecommunication equipment, including 47 CFR Part 68, and FCC interpretation thereof;</p> <p>(The Parties recognize that the FCC Form 730 Application Guide provides useful guidelines for the implementation of conformity assessment procedures for telecommunication terminal equipment falling within these regulations.);</p> <p>The U.S. regulatory and administrative provisions in respect of all radio transmitters subject to an equipment authorization requirement. A non-exclusive list of FCC regulations are contained in Section II;</p> <p>For electrical safety, see Electrical Safety Sectoral Annex to the Agreement;</p> <p>For electromagnetic compatibility aspects, see Electromagnetic Compatibility (EMC) Sectoral Annex to the Agreement.</p>

U.S. -EC MRA Telecommunication Equipment Annex

EC - U.S. MRA

**SECTORAL ANNEX
FOR
TELECOMMUNICATION EQUIPMENT**

PREAMBLE

Recognizing that this Annex constitutes a Sectoral Annex to the Agreement on Mutual Recognition of Conformity Assessment between the United States and the European Community,

U.S. -EC MRA Telecommunication Equipment Annex

SECTION II (continued)

SCOPE AND COVERAGE

EC	U.S.
<p>The following equipment categories are included :</p> <p>ISDN Basic Rate Access ISDN Primary Rate Access ISDN Telephony X21/V.24/V.35 Access X25 Access PSTN Non-Voice PSTN Voice Band (Analog) ONP Leased Line Terminal types :</p> <p>-64 kbits/sec -2048 kbits/s unstructured -2048 kbits/s structured -34 Mbits/s access -140 Mbits/s access -2 wire analogue -4 wire analogue</p> <p>Radio transmitters subject to an equipment authorization requirement, including:</p> <p>(List to be provided before signing of Sectoral Annex.)</p>	<p>Equipment categories covered under 47 CFR Part 68, including:</p> <p>ISDN Basic Access ISDN Primary Rate Access Digital Service Access :</p> <p>2.4 kbps 3.2 kbps (2.4 kbps with Secondary Channel) 4.8 kbps 6.4 kbps (4.8 kbps with SC) 9.6 kbps 12.8 kbps (9.6 kbps with SC) 19.2 kbps 25.0 kbps (19.2 kbps with SC) 56.0 kbps 64.0 kbps (uses 72 kbps channel) 72.0 kbps (56.0 kbps with SC) 1.544 Mbps 2 wires analog tie trunks/ops 4 wire analog tie trunks/ops PSTN Voice Band (Analog) Access Private Line (Analog) Access</p> <p>Radio transmitters subject to an equipment authorization requirement, including:</p> <p>Commercial Mobile Radio (Part 20) Domestic Public Fixed (Part 21) Domestic Mobile (Part 22) Personal Communication Service (Part 24) Satellite Communications (Part 25) Broadcast (Part 73) Auxiliary Broadcast (Part 74) Cable Television Radio (Part 78) Maritime (Part 80) GMDSS (Part 80W) Private Land Mobile (Part 90) Private-Fixed Microwave (Part 94) Personal Radio Services (Part 95) IVDS (Part 95 F) Amateur Radio (Part 97) Radio Frequency Devices (Part 15) Fixed Microwave Services (Part 101)</p>

Note: A list of acronyms and a glossary is contained in Appendix 1 to this Sectoral Annex.

U.S. -EC MRA Telecommunication Equipment Annex

SECTION II

SCOPE AND COVERAGE

1. This Sectoral Annex shall apply to equipment, interfaces, and services subject to Section I. In general terms the provisions of this Sectoral Annex shall apply to the following types of telecommunications terminal equipment, satellite terminal equipment, radio transmitters, and information technology equipment:
 - (a) equipment intended for connection to the public telecommunications network in order to send, process or receive information, whether the equipment is to be connected directly to the “termination” of the network or to inter-work with such a network, being connected directly or indirectly to the termination point. The system of connection may be wire, radio, optical or other electro-magnetic means;
 - (b) equipment capable of being connected to a public telecommunications network even if it is not its intended purpose, including information technology equipment having a communication port; and
 - (c) all radio transmitters subject to an equipment authorization procedure by either Party.
2. The following is a non-exclusive list of the equipment, interfaces, and services included within the scope of this Sectoral Annex:

U.S. -EC MRA Telecommunication Equipment Annex

SECTION IV

**AUTHORITIES RESPONSIBLE FOR DESIGNATING THE
CONFORMITY ASSESSMENT BODIES LISTED IN SECTION V**

EC	U.S.
<p>Austria Bundesministerium fürWissenschaft,Verkehr und Lumst.</p> <p>Belgium BIPT.</p> <p>Denmark Telestyrelsen.</p> <p>Finland Telecommunications Administration Centre</p> <p>Germany Ministerium für Post & Telecommunications.</p> <p>Greece Ministry of Transport & Communications.</p> <p>France Direction Générale des Postes & Télécommunications</p> <p>Ireland Dept. of Transport, Energy & Communications.</p> <p>Italy Ispettorato General TLC.</p> <p>Luxembourg Administration des Postes et Télécommunications.</p> <p>Netherlands Min. Verkeer en Waterstaat, Telecom, en Post Department.</p> <p>Portugal Instituto das Comunicacoes.</p> <p>Spain Ministerio de Formento</p> <p>Sweden National Post & Telecom Agency + SWEDAC.</p> <p>UK Dept of Trade & Industry .</p>	<p>National Institute of Standards and Technology (NIST)</p> <p>Federal Communications Commission (FCC)</p>

U.S. -EC MRA Telecommunication Equipment Annex

SECTION III

CONFORMITY ASSESSMENT PROCEDURES FOR TELECOMMUNICATION EQUIPMENT

1. Description of Mutual Recognition Obligations

In accordance with the provisions of the Agreement, the results of the conformity assessment procedures produced by a Party's conformity assessment bodies listed in Section V shall be recognized by the Regulatory Authorities of the other Party without any further conformity assessment of the products, pursuant to Section I.

2. Conformity Assessment Procedures

Taking into account the legislative, regulatory, and administrative provisions as identified in Section I, each Party recognizes that the conformity assessment bodies of the other Party, listed in Section V, are authorized to perform the following procedures with regard to the importing Party's technical requirements for telecommunications terminal equipment, satellite terminal equipment, radio transmitters or information technology equipment:

- a) testing and issuing of test reports;
- b) issuing certificates of conformity to the requirements of the laws and regulations applicable in the territories of the Parties for products covered under this Sectoral Annex; and
- c) performing quality assurance certification pursuant to Council Directive 91/263/EEC.

U.S. -EC MRA Telecommunication Equipment Annex

SECTION VI

**DESIGNATING, LISTING, SUSPENDING, WITHDRAWING AND MONITORING
CONFORMITY ASSESSMENT BODIES LISTED IN SECTION V**

EC	U.S.
<p><i>EC Access to U.S. Market:</i></p> <p>EC Authorities identified in Section IV shall designate conformity assessment bodies located in the EC in accordance with the U.S. legislative, regulatory, and administrative provisions identified in Section I that govern designation of conformity assessment bodies, based on compliance with the appropriate ISO/IEC Guides (e.g. Guide 22, 25, 28, 58, 61, 62, 65, etc.) or the comparable EN-45000 Series Standards.</p> <p>Procedures for designating, listing, suspending, withdrawing, and monitoring a conformity assessment body listed in Section V shall be undertaken pursuant to Articles 7, 8, 9, and 10 of the Agreement.</p>	<p><i>U.S. Access to EC Market:</i></p> <p>U.S. Authorities identified in Section IV shall designate conformity assessment bodies located in the U.S. in accordance with the EC legislative, regulatory, and administrative provisions identified in Section I that govern designation of conformity assessment bodies, based on compliance with the appropriate EN-45000 Series Standards or the comparable ISO/IEC Guides (e.g. Guide 22, 25, 28, 58, 61, 62, 65, etc.).</p> <p>Procedures for designating, listing, suspending, withdrawing, and monitoring a conformity assessment body listed in Section V shall be undertaken pursuant to Articles 7, 8, 9, and 10 of the Agreement.</p>

U.S. -EC MRA Telecommunication Equipment Annex

SECTION V

CONFORMITY ASSESSMENT BODIES

EC	U.S.
<p>Conformity assessment bodies located in the EC shall be designated by the Authorities identified in Section IV following the procedures set out in Section VI of this Annex.</p> <p><i>(to be provided by the EC upon notification by the Member States).</i></p>	<p>Conformity assessment bodies located in the U.S. shall be designated by the Authorities identified in Section IV following the procedures set out in Section VI of this Annex.</p> <p><i>(to be provided by the U.S.)</i></p>

U.S. -EC MRA Telecommunication Equipment Annex

In the event of disagreement either the U.S. or EC representative may raise the matter in the Joint Committee.

3.3 The JSC may address any matter related to the effective functioning of this Sectoral Annex, including:

- a) providing a forum for discussion of issues and resolving problems that may arise concerning the implementation of this Sectoral Annex;
- b) developing a mechanism for ensuring consistency of interpretations of legislation, regulations, standards, and conformity assessment procedures;
- c) advising the Parties on matters relating to this Sectoral Annex; and
- d) providing guidance and, if necessary, developing guidelines during the transitional period to facilitate the successful completion of the transitional period.

4. CONTACT POINT

Each Party shall establish a contact point to provide answers to all reasonable inquiries from the other Party regarding procedures, regulations, and complaints under this Sectoral Annex.

5. REGULATORY CHANGES AND UPDATING THE SECTORAL ANNEX

In the event that there are changes to the legislative, regulatory, and administrative provisions referenced in Section I or the introduction of new legislative, regulatory, and administrative provisions affecting either Party's conformity assessment procedures under the Agreement, such changes shall take effect for the purpose of this Sectoral Annex at the same time they take effect domestically within the territory of each Party. The Parties shall update this Sectoral Annex to reflect the changes.

U.S. -EC MRA Telecommunication Equipment Annex

SECTION VII

ADDITIONAL PROVISIONS

1. SUB - CONTRACTING

- 1.1 Any sub-contracting by conformity assessment bodies shall be in accordance with the sub-contracting requirements of the other Party. Notwithstanding the use of sub-contracting, the final results of conformity assessment remain the full responsibility of the listed conformity assessment body. In the EC, these requirements are described in Council Decision 93/465/EEC.
- 1.2 The conformity assessment bodies shall record and retain details of their investigation of the competence and compliance of their subcontractors and maintain a register of all sub-contracting. These details will be available to the other Party on request.

2. POST-MARKET SURVEILLANCE, BORDER MEASURES AND INTERNAL MOVEMENT

- 2.1 For the purpose of post-market surveillance, the Parties may maintain any existing labeling and numbering requirements. The assignment of the numbers may take place in the territory of the exporting Party. The numbers will be allocated by the importing Party. Numbering and labeling systems shall not introduce additional requirements within the meaning of this Sectoral Annex.
- 2.2 Nothing in this Sectoral Annex shall prevent the Parties from removing products from the market that do not in fact conform to the requirements for approval.
- 2.3 The Parties agree that border inspections and checks of products which have been certified, labeled or marked as conforming with the importing Party's requirements specified in Section I shall be completed as expeditiously as possible. With regard to any inspections related to internal movement within their respective territories, the Parties agree that these shall be completed in no less a favorable manner than for like-domestic goods.

3. JOINT SECTORAL COMMITTEE

- 3.1 A combined Joint Sectoral Committee for this Sectoral Annex and the EMC Sectoral Annex is hereby established (the JSC). The JSC shall operate during the transitional period and after completion of the transitional arrangement. The JSC shall meet as appropriate to discuss technical, conformity assessment and technology issues relating to this Sectoral Annex and the EMC Sectoral Annexes. The JSC shall determine its own rules of procedure.
- 3.2 The JSC consists of representatives of the U.S. and the EC for telecommunications and EMC. JSC representatives may each invite manufacturers and other entities as deemed necessary. The representatives for the U.S. shall have one vote in the JSC. The representatives of the EC shall have one vote in the JSC. Decisions of the JSC shall be made by unanimous consent.

U.S. -EC MRA Telecommunication Equipment Annex

7. Any proposal made during or at the end of the transitional period to limit the scope of recognition of any designated conformity assessment body or to exclude it from the list of bodies designated under this Sectoral Annex shall be based on objective criteria and documented. Any such body may apply for reconsideration once the necessary corrective action has been taken. To the extent possible, the Parties shall implement such action prior to the expiry of the transitional period.
8. The Parties may jointly sponsor two seminars, one in the U.S. and one in the European Community, concerning the relevant technical and product approval requirements during the first year after this Sectoral Annex enters into force.
9. Passage from the transitional phase into the operational phase in this Sectoral Annex shall take place provided that a representative number of conformity assessment bodies have been accepted for recognition under the Electrical Safety Annex.

U.S. -EC MRA Telecommunication Equipment Annex

SECTION VIII

TRANSITIONAL ARRANGEMENT

1. There shall be a transitional period of 24 months.
2. The purpose of this transitional arrangement is to provide a means whereby the Parties to the Agreement can build confidence in and an understanding of each other's system for designating and listing conformity assessment bodies and in the ability of these bodies to test and certify products. Successful completion of the transitional arrangement should result in the determination that conformity assessment bodies listed in Section V comply with the applicable criteria and are competent to conduct conformity assessment activities on behalf of the other Party. Upon successful completion of the transition period, the results of conformity assessment procedures performed by the exporting Party's conformity assessment bodies listed in Section V of the exporting country shall be accepted by the importing Party.
3. This transitional period shall be used by the Parties:
 - a) to consider new legislative changes needed to support the objectives of the Agreement;
 - b) to initiate regulatory changes needed to support the objectives of the Agreement;
 - c) to exchange information on and develop better understanding of their respective regulatory requirements;
 - d) to develop mutually agreed mechanisms for exchanging information on changes in technical requirements or methods of designating conformity assessment bodies; and
 - e) to monitor and evaluate the performance of the listed conformity assessment bodies during the transitional period.
4. Parties may designate, list, suspend and withdraw conformity assessment bodies during the transitional period according to the procedures in Section VI of this Sectoral Annex.
5. During the transitional period each Party shall accept and evaluate test reports and related documents issued by designated conformity assessment bodies of the other Party. To this end, the Parties shall ensure that:
 - a) on receipt of test reports, related documents and a first evaluation of conformity, the dossiers are promptly examined for completeness;
 - b) the applicant is informed in a precise and complete manner of any deficiency;
 - c) any request for additional information is limited to omissions, inconsistencies or variances from the technical regulations or standards; and
 - d) procedures for assessing the conformity for equipment modified subsequent to a determination of compliance, are limited to procedures necessary to determine continued conformance.
6. Each Party ensures that issuance of approvals, certificates, or advice to the applicant shall be given no later than six weeks from receipt of the test report and evaluation from a designated conformity assessment body in the territory of the other Party.

EU - U.S. MRA

**SECTORAL ANNEX
FOR
ELECTROMAGNETIC COMPATIBILITY (EMC)**

PREAMBLE

Recognizing that this Annex constitutes a Sectoral Annex to the framework Agreement on Mutual Recognition of Conformity Assessment between the United States and the European Community.

U.S. -EC MRA Telecommunication Equipment Annex

APPENDIX 1

LISTS OF ACRONYMS AND GLOSSARY

ACTE	Approvals Committee for Terminal Equipment
ADLNB	Association of Designated Laboratories and Notified Bodies
CAB	Conformity Assessment Body
CFR	U.S. Code of Federal Regulations, Title 47 CFR
CTR	Common Technical Regulation
EC	European Community
EEC	European Economic Community
EN	Norme Européenne (European Standard)
EU	European Union
FCC	Federal Communications Commission
IEC	International Electrotechnical Commission
ISDN	Integrated Services Digital Network
ISO	International Standards Organization
ITU	International Telecommunications Union
MRA	Mutual Recognition Agreement
MS	Member States (of the European Union)
NB	Notified Bodies
NIST	National Institute of Standards and Technology
OJ	Official Journal (of the European Union)
ONP	Open Network Provision
PSTN	Public Switched Telephone Network
STG	Sectoral Technical Group for Telecommunications
TBR	Technical Basis for Regulation
X21	ITU-T Recommendation X21
X25	ITU-T Recommendation X25

SECTION II

SCOPE AND COVERAGE

EC	U.S.
<p><i>For US access to the EU market:</i></p> <p>Any product falling under the scope of Council Directive 89/336/EEC.</p>	<p><i>For EU access to the US market:</i></p> <p>Any products falling under the scope of 47 CFR Part 15 and 18.</p>

SECTION I

LEGISLATIVE, REGULATORY AND ADMINISTRATIVE PROVISIONS

EC	U.S.
<p>Council Directive 89/336/EEC, as amended by Council Directives 91/263/EEC, 92/31/EEC, 93/68/EEC and 93/97/EEC and interpretation thereof.</p> <p>For electrical safety aspects see Electrical Safety Sectoral Annex to the Agreement.</p> <p>For telecommunication equipment and radio transmitters, see also Telecommunications Equipment Sectoral Annex to the Agreement.</p>	<p>Communications Act of 1934, as amended by the Telecommunication Act of 1996, (Title 47 of the United States Code),</p> <p>the U.S. regulatory and administrative provisions in respect of equipment subject to electromagnetic requirements including:</p> <ul style="list-style-type: none">- 47 CFR Part 15- 47 CFR Part 18, <p>and FCC interpretation thereof.</p> <p>For electrical safety aspects see Electrical Safety Sectoral Annex to the Agreement.</p> <p>For telecommunication equipment and radio transmitters, see also Telecommunications Equipment Sectoral Annex to the Agreement.</p>

SECTION IV

**AUTHORITIES RESPONSIBLE FOR DESIGNATING THE
CONFORMITY ASSESSMENT BODIES LISTED IN SECTION V**

EU	U.S.
Austria: Bundesministerium für wirtschaftliche Angelegenheiten Abteilung	National Institute of Standards and Technology (NIST)
Belgium:	Federal Communications Commission (FCC)
Denmark:	
Finland:	
France:	
Germany:	Federal Aviation Administration (FAA)
Greece:	
Ireland:	
Italy:	
Luxemburg:	
Netherlands:	
Portugal:	
Spain:	
Sweden:	
U.K.:	
(list to be completed later)	

SECTION III

**CONFORMITY ASSESSMENT PROCEDURES
FOR EQUIPMENT IDENTIFIED IN SECTION II**

1. Description of Mutual Recognition Obligations

In accordance with the provisions of the Agreement, the results of the conformity assessment procedures produced by a Party's conformity assessment bodies listed in Section V, shall be recognized by the Regulatory Authorities of the other Party without any further conformity assessment of the products, pursuant to Section I.

2. Conformity Assessment Procedures

Taking into account the legislative, regulatory, and administrative provisions as identified in Section I, each Party recognizes that the conformity assessment bodies of the other Party, listed in Section V, are authorized to perform the following procedures with regard to the importing Party's technical requirements for equipment identified in Section II:

- a) testing and issuing of test reports;
- b) issuing certificates of conformity to the requirements of the laws and regulations applicable in the territories of the Parties for products covered under this Sectoral Annex.

SECTION VI

DESIGNATING, LISTING, SUSPENDING, WITHDRAWING AND MONITORING
CONFORMITY ASSESSMENT BODIES LISTED IN SECTION V

EC	U.S.
<p><i>EC Access to U.S. Market:</i></p> <p>EC Authorities identified in Section IV shall designate conformity assessment bodies located in the EC in accordance with the U.S. legislative, regulatory, and administrative provisions identified in Section I that govern designation of conformity assessment bodies, based upon compliance with the appropriate ISO/IEC Guides (e.g. Guide 22, 25, 28, 58, 61, 62, 65, etc.) or the comparable EN-45000 Series Standards.</p> <p>Procedures for designating, listing, suspending, withdrawing, and monitoring a conformity assessment body listed in Section V shall be undertaken pursuant to Articles 7, 8, 9, and 10 of the Agreement.</p>	<p><i>U.S. Access to EC Market:</i></p> <p>U.S. Authorities identified in Section IV shall designate conformity assessment bodies located in the U.S. in accordance with the EC legislative, regulatory, and administrative provisions identified in Section I that govern designation of conformity assessment bodies, based on compliance with the appropriate EN-45000 Series Standards or the comparable ISO/IEC Guides (e.g. Guide 22, 25, 28, 58, 61, 62, 65, etc.).</p> <p>Procedures for designating, listing, suspending, withdrawing, and monitoring a conformity assessment body listed in Section V shall be undertaken pursuant to Articles 7, 8, 9, and 10 of the Agreement.</p>

SECTION V

CONFORMITY ASSESSMENT BODIES

EC	U.S.
<p><i>For EC access to the U.S. market:</i></p> <p>Conformity assessment bodies located in the EC shall be designated by the Authorities identified in Section IV following the procedures set out in Section VI of this Annex.</p> <p>(to be provided by the EC)</p>	<p><i>For U.S. access to the EC market:</i></p> <p>Conformity assessment bodies located in the U.S. shall be designated by the Authorities identified in Section IV following the procedures set out in Section VI of this Annex.</p> <p>(to be provided by the U.S.)</p>

US-EC MRA -- EMC SECTORAL ANNEX

- 3.2 The JSC consists of representatives of the U.S. and the EC for telecommunications and EMC. JSC representatives may each invite manufacturers and other entities as deemed necessary. The representatives for the U.S. shall have one vote in the JSC. The representatives of the EC shall have one vote in the JSC. Decisions of the JSC shall be made by unanimous consent. In the event of disagreement either the U.S. or EC representatives may raise the matter in the Joint Committee.
- 3.3 The JSC may address any matter related to the effective functioning of this Sectoral Annex, including :
- a) providing a forum for discussion of issues and resolving problems that may arise concerning the implementation of this Sectoral Annex;
 - b) developing a mechanism for ensuring consistency of interpretations of legislation, regulations, standards, and conformity assessment procedures.
 - c) advising the Parties on matters relating to this Sectoral Annex;
 - d) providing guidance and, if necessary, developing guidelines during the transitional period to facilitate the successful completion of the transitional period.

4. CONTACT POINT

Each Party shall establish a contact point to provide answers to all reasonable inquiries from the other Party regarding procedures, regulations and complaints under this Sectoral Annex.

5. REGULATORY CHANGES AND UPDATING THE SECTORAL ANNEX

In the event that there are changes to the legislative, regulatory and administrative provisions referenced in Section I or the introduction of new legislative, regulatory and administrative provisions affecting either Party's conformity assessment procedures under the Agreement, such changes shall take effect for the purpose of this Sectoral Annex at the same time they take effect domestically within the territory of each Party. The Parties shall update this Sectoral Annex to reflect the changes.

**SECTION VII
ADDITIONAL PROVISIONS**

1. SUB - CONTRACTING
 - 1.1 Any sub-contracting by conformity assessment bodies shall be in accordance with the sub-contracting requirements of the other Party. Notwithstanding the use of sub-contracting, the final results of conformity assessment remain the full responsibility of the listed conformity assessment body. In the EC, these requirements are described in Council Decision 93/465/EEC.
 - 1.2 The conformity assessment bodies shall record and retain details of its investigation of the competence and compliance of its subcontractors and maintain a register of all sub-contracting. These details will be available to the other Party on request.
2. POST-MARKET SURVEILLANCE, BORDER MEASURES AND INTERNAL MOVEMENT
 - 2.1 For the purpose of post-market surveillance, the Parties may maintain any existing labeling and numbering requirements. The assignment of the numbers may take place in the territory of the exporting Party. The numbers will be allocated by the importing Party. Numbering and labeling systems shall not introduce additional requirements within the meaning of this Sectoral Annex.
 - 2.2 Nothing in this Sectoral Annex shall prevent the Parties from removing products from the market that do not in fact conform to the requirements for approval.
 - 2.3 The Parties agree that border inspections and checks of products which have been certified, labeled or marked as conforming with the importing Party's requirements specified in Section I shall be completed as expeditiously as possible. With regard to any inspections related to internal movement within their respective territories, the Parties agree that these shall be completed in no less a favorable manner than for like-domestic goods.
3. JOINT SECTORAL COMMITTEE
 - 3.1 A combined Joint Sectoral Committee for this Sectoral Annex and the Telecommunications Equipment Sectoral Annex is hereby established (the JSC). The JSC shall operate during the transitional period and after completion of the transitional arrangement. The JSC shall meet as appropriate to discuss technical, conformity assessment and technology issues relating to this Sectoral Annex and the Telecommunications Equipment Sectoral Annex. The JSC shall determine its own rules of procedure.

US-EC MRA -- EMC SECTORAL ANNEX

6. Each Party ensures that issuance of approvals, certificates or advice to the applicant shall be given no later than six weeks from receipt of the test report and evaluation from a designated conformity assessment body in the territory of the other Party.
7. Any proposal made during or at the end of the transitional period to limit the scope of recognition of any designated conformity assessment body or to exclude it from the list of bodies designated under this Sectoral Annex shall be based on objective criteria and documented. Any such body may apply for reconsideration once the necessary corrective action has been taken. To the extent possible, the Parties shall implement such action prior to the expiry of the transitional period.
8. The Parties may jointly sponsor two seminars, one in U.S. and one in the European Community, concerning the relevant technical and product approval requirements during the first year after this Sectoral Annex enters into force.
9. Passage from the transitional phase into the operational phase in this Sectoral Annex shall take place provided that a representative number of conformity assessment bodies have been accepted for recognition under the Electrical Safety Annex.

SECTION VIII

TRANSITIONAL ARRANGEMENT

1. There shall be a transitional period of 24 months.
2. The purpose of this transitional arrangement is to provide a means whereby the Parties to the Agreement can build confidence in and understanding of each others system for designating and listing conformity assessment bodies and in the ability of these bodies to test and certify products. Successful completion of the transition arrangement should result in the determination that conformity assessment bodies listed in Section V comply with the applicable criteria and are competent to conduct conformity assessment activities on behalf of the other Party. Upon completion of the transition period, the results of conformity assessment procedures performed by the exporting Party's conformity assessment bodies listed in Section V shall be accepted by the importing Party.
3. This transitional period shall be used by the Parties :
 - a) to consider new legislative changes needed to support the objectives of the Agreement;
 - b) to initiate regulatory changes needed to support the objectives of the Agreement;
 - c) to exchange information on and develop better understanding of their respective regulatory requirements;
 - d) to develop mutually agreed mechanisms for exchanging information on changes in technical requirements or methods of designating conformity assessment bodies; and
 - e) to monitor and evaluate the performance of the listed conformity assessment bodies during the transitional period.
4. Parties may designate, list, suspend and withdraw conformity assessment bodies during the transitional period according to the procedures in Section VI of this Sectoral Annex.
5. During the transitional period each Party shall accept and evaluate test reports and related documents issued by designated conformity assessment bodies of the other Party. To this end, the Parties shall ensure that:
 - on receipt of test reports, related documents and a first evaluation of conformity, the dossiers are promptly examined for completeness;
 - the applicant is informed in a precise and complete manner of any deficiency;
 - any request for additional information is limited to omissions, inconsistencies or variances from the technical regulations or standards;
 - procedures for assessing the conformity for equipment modified subsequent to a determination of compliance. are limited to procedures necessary to determine continued conformance;

SECTION I

LEGISLATIVE, REGULATORY AND ADMINISTRATIVE PROVISIONS

EC

U.S.

<p><i>For U.S. access to the EC market:</i></p> <p>Council Directive 73/23/EEC of 19 February 1973 as amended by 93/68/EEC.</p> <p>For medical devices, see the Medical Devices Sectoral Annex to this Agreement.</p> <p>For electromagnetic compatibility aspects, see the Electromagnetic Compatibility (EMC) Sectoral Annex to this Agreement.</p> <p>For telecommunications equipment, see the Telecommunications Equipment Sectoral Annex to this Agreement.</p>	<p><i>For EC access to the U.S. market</i></p> <p>29 U.S.C. 651 et seq. U.S. 29 CFR 1910.7</p> <p>Products that are certified or approved under the Federal Mine Safety and Health Act (30 U.S.C. 801 et seq.) or its regulations and used in areas under the authority of the Mine Safety and Health Administration, are not covered under this Annex.</p> <p>OSHA will consider regulatory and legislative changes needed to support the objectives of the MRA.</p> <p>For medical devices, see the Medical Devices Sectoral Annex to this Agreement.</p> <p>For electromagnetic compatibility aspects, see the Electromagnetic Compatibility (EMC) Sectoral Annex to this Agreement.</p> <p>For telecommunications equipment, see the Telecommunications Equipment Sectoral Annex to this Agreement.</p>
---	---

U.S.-EC MRA - Electrical Safety Annex

EC - U.S. MRA

**SECTORAL ANNEX
FOR
ELECTRICAL SAFETY**

PREAMBLE

Recognizing that this Annex constitutes a Sectoral Annex to the Agreement on Mutual Recognition between the United States and the European Community.

U.S.-EC MRA - Electrical Safety Annex

SECTION III

Description of Mutual Recognition Obligations

In accordance with the provisions of the Agreement, EC conformity assessment bodies listed in Section V of this Annex shall be recognized to test, certify and mark products within the scope of their NRTL recognition for assessing conformity to U.S. requirements.

With regard to U.S. conformity assessment bodies listed in Section V of this Annex, in the event of a challenge within the European Community under Article 8.2 of Council Directive 73/23/EEC of 19 February 1973, test reports issued by such conformity assessment bodies shall be accepted by the European Community Authorities in the same way that reports from European Community Notified Bodies are accepted. That is, (listed conformity assessment bodies) in the U.S. shall be recognized under Article 11 of Council Directive 73/23/EEC as "bodies which may make a report in accordance with Article 8."

SECTION II
SCOPE AND COVERAGE

EC

U.S.

<p><i>For U.S. access to the EC market:</i></p> <p>The electrical safety requirements of products falling under the scope of Council Directive 73/23/EEC on the harmonization of the laws of the Member States relating to electrical equipment designed for use within certain voltage limits.</p>	<p><i>For EC access to the U.S. market:</i></p> <p>The electrical safety requirements of products falling under the scope of 29 CFR 1910 subpart S. This includes the electrical safety aspects for workplace safety of medical equipment and telecommunication terminal equipment within the scope of those Sectoral Annexes.</p> <p>Products that are certified or approved under the Federal Mine Safety and Health Act (30 U.S.C. 801 <u>et seq.</u>) or its regulations and used in areas under the authority of the Mine Safety and Health Administration, are not covered under this Annex.</p>

SECTION V

CONFORMITY ASSESSMENT BODIES

EC

U.S.

<p><i>For EC access to the U.S. market:</i></p> <p>The names and scope of responsibilities of Conformity Assessment Bodies located in the EC and listed in accordance with this Sectoral Annex:</p>	<p><i>For U.S. access to the EC market:</i></p> <p>The names and scope of responsibilities of Conformity Assessment Bodies located in the U.S. and listed in accordance with this Sectoral Annex:</p>
---	---

[An initial list of Conformity Assessment Bodies should be listed in this Section by the time we implement the Agreement.**]**

SECTION IV

**AUTHORITIES RESPONSIBLE FOR DESIGNATING THE
CONFORMITY ASSESSMENT BODIES LISTED IN SECTION V**

EC

U.S.

<p><i>For EC access to the U.S. market:</i></p> <p>Member State Authorities:</p> <p>Austria: Bundesministerium fur Wirtschaft Belgium: Ministère de l'Emploi et du Travail Danmark: Direktoratet for Arbejdstilsynet Finland: Ministry of Labour France: Ministère de l'Emploi et du Travail Germany: Bundesmin. fur Arbeit und Sozialordnung</p> <p>Greece: Ministry of Industry Ireland: Departm. of Enterprise and Employment</p> <p>Italy: Ministero dell' Industria Luxemburg: Ministère du Travail Netherlands: Min van Sociale Zaken en Werkgelegenheid Portugal: Ministerio Industria e Energia Spain: Min. de Fomento Sweden: National Board of Occupation & Safety U.K. Department of Trade & Industry</p>	<p><i>For U.S. access to the EC market:</i></p> <p>National Institute for Standards and Technology (NIST)</p>
--	--

U.S.-EC MRA - Electrical Safety Annex

SECTION VI (continued)

Upon receipt of a complete proposal, the U.S. exercising its authority under its law shall:

(a) prior to the passage from the transitional phase into the operational phase in the Telecommunications Equipment and Electromagnetic Compatibility (EMC) Sectoral Annexes, give notice of its consent or objection to a proposed conformity assessment body to the Joint Committee. The listing of an agreed conformity assessment body in Section V of this Sectoral Annex shall only occur upon such passage from the transitional phase into the operational phase of those Sectoral Annexes.

(b) subsequent to passage from the transitional phase into the operational phase in the Telecommunications Equipment and Electromagnetic Compatibility (EMC) Sectoral Annexes, give notice of its consent or objection to a proposed conformity assessment body to the Joint Committee normally within 120 business days. The listing of an agreed conformity assessment body in Section V of this Sectoral Annex shall occur upon notice of consent to the Joint Committee and the Joint Committee's decision to list such body.

These listing procedures shall supersede the procedures in Article 7(c) of the Agreement in its entirety and the time periods set out in Article 7(d) of the Agreement.

EC conformity assessment bodies listed in Section V shall have NRTL status in the U.S.

With regard to the suspension of a conformity assessment body listed in this Sectoral Annex, the period specified in Article 8(e) of the Agreement shall begin to run after a Party has notified the Joint Sectoral Committee or the Joint Committee, pursuant to Article 8(c) of the Agreement, that it proposes to revoke the conformity assessment body's recognition in accordance with its procedures under its applicable domestic law.

Except as provided for in this Section, procedures for designation, listing, suspension and withdrawal of conformity assessment bodies under this Sectoral Annex shall be carried out in accordance with Articles 7, 8 and 9 of the Agreement.

Upon receipt of a complete proposal, the EC shall give notice of consent or objection to the Joint Committee within 60 days. The Joint Committee shall monitor the recognition of conformity assessment bodies and confirm such a recognition by listing them in Section V of this Sectoral Annex.

The U.S. conformity assessment bodies listed in Section V shall have Notified Body status within the EC.

SECTION VI

DESIGNATING, LISTING, SUSPENDING AND WITHDRAWING
CONFORMITY ASSESSMENT BODIES

EC

U.S.

For EC access to the U.S. market:

Conformity assessment bodies from the EC shall be designated by the EC Authorities identified in Section IV and recognized by the Joint Committee, in accordance with the recognition procedures in the Agreement and this Annex.

Conformance with the appropriate ISO/IEC Guides or the corresponding EN 4500 series of standards shall be deemed consistent with U.S. requirements identified in Section I.

For purposes of designation and listing, EC Designating Authorities identified in Section IV shall designate conformity assessment bodies located in the EC by filing a properly prepared proposal for listing, which includes a complete lab assessment under the U.S. OSHA procedures. OSHA shall notify the EC Designating Authority normally within 30 days as to whether the proposal is complete or whether additional information is required.

OSHA shall rely on the EC Designating Authorities identified in Section IV for conducting on-site reviews at the respective Member States' conformity assessment bodies.

For U.S. access to the EC market:

Conformity assessment bodies from the U.S. shall be designated by the U.S. Authority identified in Section IV and recognized by the Joint Committee, in accordance with the recognition procedures in the Agreement and Council Directive 73/23/EEC.

Conformance with the appropriate EN 4500 series of standards or the corresponding ISO/IEC Guides shall be deemed consistent with the requirements of Council Directive 73/23/EEC.

For purposes of designating and listing, the U.S. Designating Authority identified in Section IV shall designate conformity assessment bodies located in the U.S. by filing a properly prepared proposal for listing with the EC, which includes a complete lab assessment under the following EC or Member State procedures, as appropriate:

The EC shall notify the U.S. Designating Authority within 30 days as to whether the proposal is complete and shall indicate, where applicable, any additional information that is required.

SECTORAL ANNEX
FOR
RECREATIONAL CRAFT

This Annex constitutes a Sectoral Annex to the Agreement on Mutual Recognition between the United States and the European Community.

The purpose of this Sectoral Annex is to establish a framework to accept certificates of conformity issued in the territory of one Party in accordance with the regulatory requirements of the other Party as referenced in this Sectoral Annex.

To facilitate that purpose, a transitional period of eighteen months is arranged to build confidence as defined in this Sectoral Annex, Section 6.

SECTION VII

JOINT SECTORAL COMMITTEE FOR ELECTRICAL SAFETY

1. The Joint Sectoral Committee for Electrical Safety (JCS/ES) consists of representatives of the U.S. and the EC. OSHA shall represent the U.S. on this Joint Sectoral Committee. The EC and OSHA may invite the participation of others as deemed necessary. Each Party shall have one vote and decisions shall be made by unanimous consent, unless otherwise specified herein. The Joint Sectoral Committee shall determine its own rules of procedure.
2. The Joint Sectoral Committee may address any matter related to the effective functioning of this Sectoral Annex, including :
 - Developing improved procedures and criteria for designation in order to facilitate the assessment and preparation of proposals by Designating Authorities, with a view towards expediting the period between designation and listing;
 - providing a forum for discussion of issues that may arise concerning the implementation of this Sectoral Annex;
 - advising the Parties on matters relating to this Sectoral Annex; and
 - enhancing the operation of this Sectoral Annex.

U.S.-EC MRA - RECREATIONAL CRAFT ANNEX

All products covered by Section 2 of this Annex.

5. Cooperation

During this transitional period, both Parties shall endeavor to jointly sponsor seminars for the purpose of improving the understanding of technical specifications applicable in each Party's jurisdiction.

6. Inspections

Inspections or audits shall be permitted to verify compliance of conformity assessment bodies with their responsibilities under this Agreement. The scope of these inspections or audits shall be agreed upon in advance by both Parties.

SECTION 7

ADDITIONAL PROVISIONS

1. In accordance with the relevant provisions of the Agreement, the Parties shall ensure the continued availability of the names of their respective notified bodies or conformity assessment bodies, and shall regularly supply details of certifications issued in order to facilitate post market surveillance.
2. The Parties note that, to the extent that requirements for electrical safety or electromagnetic compatibility may apply to products covered by this Sectoral Annex, the provisions of the Sectoral Annexes on Electrical Safety and Electromagnetic Compatibility apply.

SECTION 8

DEFINITIONS

"Notified Body", means a third party authorized to perform the conformity assessment tasks specified in Directive 94/25 EEC, which has been appointed by a Member State from the bodies falling within its jurisdiction. The Notified Body has the necessary qualifications to meet requirements laid down in Directive 94/25 EEC and has been notified to the Commission and to the other Member States.

U.S.-EC MRA - RECREATIONAL CRAFT ANNEX

Agreement shall be followed.

SECTION 5

CONFORMITY ASSESSMENT BODIES

1. **European Community**

The conformity assessment bodies designated by the European Community are those Notified Bodies which have been notified by the Member States of the Community, in accordance with Directive 94/25 EEC, and whose names and reference numbers have been published in the Official Journal of the European Communities.

2. **United States**

[To be provided by U.S.]

SECTION 6

TRANSITIONAL ARRANGEMENT

1. There shall be a transitional period of 18 months prior to the operations of this Sectoral Annex.
2. The purpose of the transitional arrangement is to provide a means whereby the Parties to this Agreement can cooperate to establish a system for designating conformity assessment bodies and can mutually build confidence in the abilities of these bodies. Successful completion of this transitional arrangement is intended to result in a determination that conformity assessment bodies comply with the applicable criteria and to have the equipment approved by the conformity assessment bodies of the exporting country accepted by the approval authority of the importing country
3. During this transitional period, the parties shall:
 - (a) exchange information on technical data and conformity assessment criteria and procedures, thus developing greater familiarity with their respective regulatory requirements; and
 - (b) carry out or recommend any applicable policy, legislative and regulatory changes necessary for the provisions of this Annex.
4. **Product Scope**

U.S.-EC MRA - RECREATIONAL CRAFT ANNEX

- (b) for approvals to United States requirements, conformity assessment bodies designated by the European Community shall establish compliance as required to be demonstrated as set forth in paragraph 2(b) of this Section and products so certified shall have unrestricted access to the U.S. market for sale as recreational craft, pursuant to Section 1.

SECTION 3

AUTHORITIES RESPONSIBLE FOR DESIGNATING THE CONFORMITY ASSESSMENT BODIES

1. For the European Community:

Member States Administrations as indicated in the Directive 94/25 EEC, Article 9.1.

2. For the United States:

National Institute of Standards and Technology (NIST).

SECTION 4

DESIGNATING, LISTING, SUSPENDING AND WITHDRAWING CONFORMITY ASSESSMENT BODIES

1. For the purpose of this Sectoral Annex, each party shall designate competent conformity assessment bodies to carry out conformity assessment and approval to the requirements of the other Party. Such designation shall be carried out according to the procedures set out in Article 7 of the Agreement. A list of conformity assessment bodies together with the products and procedures for which they have been listed, is in Section 5 below.
2. Each Party agrees that the listed conformity assessment bodies comply with the requirements for such bodies established by the other Party. These are:
 - (a) for the European Community, bodies which are Notified Bodies in accordance with Directive 94/25 EEC, are deemed to be in compliance with U.S. requirements;
 - (b) for the U.S., in accordance with the requirements set out in the regulations listed in Section 1, the conformity assessment bodies listed in Section 5 are designated by NIST using the evaluation procedures contained in the appropriate EN 45000 series of standards or the corresponding ISO/IEC Guides.
3. With regard to the designation, listing, suspension and withdrawal of conformity assessment bodies under this Sectoral Annex, the specific procedures in Articles 7, 8 and 9 of the

SECTION 1

LEGISLATIVE, REGULATORY, AND ADMINISTRATIVE REQUIREMENTS

1. For the European Community:

European Parliament and European Council Directive 94/25 EEC on the Approximation of the Laws, Regulations, and Administrative Provisions of the Member States Relating to Recreational Craft.

2. For the U.S.:

46 U.S.C. Chapter 43, 33 CFR 81, 84, 159, 179, 181, 183 and 46 CFR 58.

SECTION 2

SCOPE AND COVERAGE

1. This Sectoral Annex applies to all recreational craft which in the European Community or the United States are subject to conformity assessment by a conformity assessment body or an approval procedure, as applicable, before being put on the market.

2. The product coverage for each Party shall be determined by the following relevant requirements:

(a) for the European Community:

Recreational craft as defined in Directive 94/25 EEC.

(b) for the United States:

Any product falling under the scope of 46 U.S.C. Chapter 43, 33 CFR 81, 84, 159, 179, 181, 183 and 46 CFR 58.

3. The Parties agree that for mutual recognition to operate under this Sectoral Annex, the following arrangements shall apply:

(a) for approvals to European Community requirements, conformity assessment bodies designated by the U.S. shall establish compliance as required to be demonstrated by Directive 94/25 EEC. This demonstration of compliance shall be recognized in the European Community and products so certified shall have

unrestricted access to the EC market for sale as recreational craft, pursuant to Section 1.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

DEFINITIONS, PURPOSE, SCOPE AND COVERAGE

Article 1


Definitions

1. *“Equivalence”* of the regulatory systems means that the systems are sufficiently comparable to assure that the process of inspection and the ensuing inspection reports will provide adequate information to determine whether respective statutory and regulatory requirements of the authorities have been fulfilled. *“Equivalence”* does not require that the respective regulatory systems have identical procedures.
2. *“Enforcement”* means action taken by an authority to protect the public from products of suspect quality, safety and efficacy or to assure that products are manufactured in compliance with appropriate laws, regulations, standards and commitments made as part of the approval to market a product.
3. *“Good Manufacturing Practices”* : (tentative merging of US and EC concepts to be revisited)

GMPs mean the requirements found in the respective legislations, regulations, and administrative provisions for methods to be used in, and the facilities or controls to be used for, the manufacturing, processing, packing, and/or holding of a drug to assure that such drug meets the requirements as to safety, and has the identity and strength, and meets the quality and purity characteristics that it purports or is represented to process.

GMPs are that part of quality assurance which ensures that products are consistently produced and controlled to quality standards. For the purpose of this Annex, GMPs include therefore the system whereby the manufacturer receives the specifications of the product and/or process from the Marketing Authorization/Product Authorization or License holder or applicant and ensures the product is made in compliance with its specifications (Qualified Person certification in the EC).

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX



SECTORAL ANNEX

FOR

PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs)

PREAMBLE

Recognizing that this Annex constitutes a Sectoral Annex to the framework Agreement on Mutual Recognition between the United States and the European Community.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

Article 4

Product coverage

These provisions will apply to medicinal products for human or animal use, intermediates and starting materials (as referred to in the EU) and to drugs for human or animal use, biological products for human use, and active pharmaceutical ingredients (as referred to in the United States), only to the extent they are regulated by the authorities of both Parties as listed in Appendix 2.

Human blood, human plasma, human tissues and organs, and veterinary immunologicals are excluded from the scope of this Annex. Human plasma derivatives (such as immunoglobulins and albumin), investigational medicinal products/new drugs, human radiopharmaceuticals and medicinal gases are also excluded during the transition phase, their situation will be reconsidered at the end of the transition period. Products regulated by the Center for Biologics Evaluation and Research as devices are not covered under this Annex.

Appendix 3 contains an indicative list of products covered by this Annex.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

4. *“Inspection”* means an on-site evaluation of a manufacturing facility to determine whether such manufacturing facility is operating in compliance with Good Manufacturing Practices and/or commitments made as part of the approval to market a product.
5. *“Inspection Report”* means the written observations and Good Manufacturing Practices compliance assessment completed by an authority listed in Appendix 2.
6. *“Regulatory System”* means the body of legal requirements for Good Manufacturing Practices, inspections, and enforcements that ensure public health protection and legal authority to assure adherence to these requirements.

Article 2

Purpose

The provisions of this Annex govern the exchange between the Parties and normal endorsement by the receiving authority of official Good Manufacturing Practices (GMP) inspection reports after a transitional period aimed at determination of the equivalence of the regulatory systems of the Parties, which is the cornerstone of this Annex.

Article 3

Scope

The provisions of this Annex shall apply to pharmaceutical inspections carried out in the United States and Member States of the European Community before products are marketed (hereafter referred to as “pre-approval inspections”) as well as during their marketing (hereafter referred to as “post-approval inspections”).

Appendix 1 names the laws, regulations and administrative provisions governing these inspections and the GMP requirements.

Appendix 2 lists the authorities participating in activities under this Annex.

Articles 6, 7, 8, 9, 10 and 11 of the Agreement do not apply to this Annex.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

Article 7

Participation in the equivalence assessment and determination

The authorities listed in Appendix 2 will actively participate in these programs to build a sufficient body of evidence for their equivalence determination. Both parties will exercise good faith efforts to complete equivalence assessment as expeditiously as possible to the extent the resources of the authorities allow.

Article 8

Other transition activities

As soon as possible, the authorities will jointly determine the essential information which must be present in inspection reports and will cooperate to develop mutually agreed inspection report format(s).

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

**CHAPTER 2
TRANSITION PERIOD**

Article 5
Length of transition period

A three-year transition period will start immediately after the effective date of the Agreement.

Article 6
Equivalence assessment

1. The criteria to be used by the Parties to assess equivalence are listed in Appendix 4. Information pertaining to the criteria under Community competence will be provided by the Community.
2. The authorities of the parties will establish and communicate to each other their draft programs for assessing the equivalence of the respective regulatory systems in terms of quality assurance of the products and consumer protection. These programs will be carried out, as deemed necessary by the authorities, for post- and pre-approval inspections and for various product classes or processes.
3. The equivalence assessment shall include information exchanges (including inspection reports), joint training, and joint inspections for the purpose of assessing regulatory systems and the authorities' capabilities. In conducting the equivalence assessment, the Parties will ensure that efforts are made to save resources.
4. Equivalence assessment for authorities added to Appendix 2 after the effective date of this agreement will be conducted as described in this Annex, as soon as practicable.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

CHAPTER 4

OPERATIONAL PERIOD

Article 11

Start of the operational period

The operational period shall start at the end of the transition period and its provisions apply to inspection reports generated by authorities listed as equivalent for the inspections performed in their territory.

In addition, when an authority is not listed as equivalent based on adequate experience gained during the transition period, the FDA will accept for normal endorsement (as provided in Article 12) inspection reports generated as a result of inspections conducted jointly by that authority on its territory and another authority listed as equivalent, provided that the authority of the Member State in which the inspection is performed can guarantee enforcement of the findings of the inspection report and require that corrective measures be taken when necessary. FDA has the option to participate in these inspections, and based on experience gained during the transition period, the Parties will agree on procedures for exercising this option.

In the EC, the qualified person will be relieved of responsibility for carrying the controls laid down in Article 22 paragraph 1(b) of Council Directive 75/319/EEC provided that these controls have been carried out in the United States and that each batch/lot is accompanied by a batch certificate (in accordance with the WHO certification scheme on the quality of medicinal products) issued by the manufacturer certifying that the product complies with requirements of the marketing authorization and signed by the person responsible for releasing the batch/lot.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

CHAPTER 3
END OF TRANSITION PERIOD

Article 9
Equivalence determination

Equivalence is established by having in place regulatory systems covering the criteria referred to in Appendix 4, and a demonstrated pattern of consistent performance in accordance with these criteria. A list of authorities determined as equivalent shall be agreed to by the Joint Sectoral Committee at the end of the transition period, with reference to any limitation in terms of inspection type (e.g. post-approval or pre-approval) or product classes or processes.

The Parties will document insufficient evidence of equivalence, lack of opportunity to assess equivalence or a determination of non-equivalence, in sufficient detail to allow the authority being assessed to know how to attain equivalence.

Article 10
Authorities not listed as currently equivalent

Authorities not currently listed as equivalent, or not equivalent for certain types of inspections, product classes or processes may apply for reconsideration of their status once the necessary corrective measures have been taken or additional experience is gained.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

Article 14

Transmission of pre-approval inspection reports

A preliminary notification that an inspection may have to take place will be made as soon as possible.

Within 15 calendar days, the relevant authority will acknowledge receipt of the request and confirm its ability to carry out the inspection. In the EC, requests will be sent directly to the relevant authority, with a copy to the European Agency for the Evaluation of Medicinal Products (EMA). If the authority receiving the request cannot carry out the inspection as requested, the requesting authority shall have the right to conduct the inspection.

Reports of pre-approval inspections will be sent within 45 calendar days of the request that transmitted the appropriate information and detailed the precise issues to be addressed during the inspection. A shorter time may be necessary in exceptional cases and these will be described in the request.

Article 15

Monitoring continued equivalence

Monitoring activities for the purpose of maintaining equivalence shall include review of the exchange of inspection reports and their quality and timeliness; performance of a limited number of joint inspections; and the conduct of common training sessions.

Article 16

Suspension

Each Party has the right to contest the equivalence of an authority. This right will be exercised in an objective and reasoned manner in writing to the other Party.

The issue shall be discussed in the Joint Sectoral Committee promptly upon such notification. Where the JSC determines that verification of equivalence is required, it may be carried out jointly by the Parties in a timely manner, pursuant to Article 6.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

Article 12

Nature of recognition of inspection reports

Inspection reports (containing information as established under Article 8), including a GMP compliance assessment, prepared by authorities listed as equivalent, will be provided to the authority of the importing Party. Based on the determination of equivalence in light of the experience gained, these inspection reports will normally be endorsed by the authority of the importing Party, except under specific and delineated circumstances. Examples of such circumstances include indications of material inconsistencies or inadequacies in an inspection report, quality defects identified in the post-market surveillance or other specific evidence of serious concern in relation to product quality or consumer safety. In such cases, the authority of the importing Party may request clarification from the authority of the exporting Party which may lead to a request for re-inspection. The authorities will endeavor to respond to requests for clarification in a timely manner.

Where divergence is not clarified in this process, an authority of the importing country may carry out an inspection of the production facility.

Article 13

Transmission of post-approval inspection reports

Post-approval GMP inspection reports concerning products covered by this Annex will be transmitted to the authority of the importing country within 60 calendar days of the request. Should a new inspection be needed, the inspection report will be transmitted 90 calendar days of the request.

CHAPTER 5
JOINT SECTORAL COMMITTEE

Article 17

Role and composition of the Joint Sectoral Committee

A Joint Sectoral Committee is set up to monitor the activities under both the **transitional and operational phases of this Annex.**

The Committee will be co-chaired by a representative of FDA for the US and a representative of the EC who each will have one vote. **Decisions will be taken by unanimous consent.**

The Joint Sectoral Committee's functions will include:

1. **making a joint assessment, which must be agreed by both Parties, of the equivalence of the respective authorities,**
2. **developing and maintaining the list of equivalent authorities, including any limitation in terms of inspecting type or products, and communicating the list to all authorities and the Joint Committee,**
3. **providing a forum to discuss issues relating to this Annex, including concerns that an authority may be no longer equivalent and opportunity to review product coverage,**
4. **consideration of the issue of suspension.**

The Joint Sectoral Committee shall meet at the request of either Party and, unless the co-chairs otherwise agree, at least once each year. The Joint Committee will be kept informed of the agenda and conclusions of meetings of the Joint Sectoral Committee.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

Efforts will be made by the Joint Sectoral Committee to reach unanimous consent on the appropriate action. If agreement to suspend is reached in the Joint Sectoral Committee, an authority may be suspended immediately thereafter. If no agreement is reached in the Joint Sectoral Committee, the matter is referred to the Joint Committee. If no unanimous consent is reached within 30 days after such notification, the contested authority will be suspended.

Upon the suspension of an authority previously listed as equivalent, a Party is no longer obligated to normally endorse the inspection reports of the suspended authority. A Party shall continue to normally endorse the inspection reports of that authority prior to suspension, unless the authority of the receiving party decides otherwise based on health or safety considerations. The suspension will remain in effect until unanimous consent has been reached by the Parties on the future status of that authority.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

**CHAPTER 7
SAFEGUARD CLAUSE**

Article 21

Each Party recognizes that the importing country has a right to fulfill its legal responsibilities by taking actions necessary to ensure the protection of human and animal health at the level of protection it deems appropriate. This includes the suspension of the distribution, product detention at the border of the importing country, withdrawal of the batches and any request for additional information or inspection as provided in Article 12.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

**CHAPTER 6
INFORMATION EXCHANGE**

Article 18

Regulatory collaboration

The Parties and authorities shall inform and consult one another, as permitted by law, on proposals to introduce new controls or to change existing technical regulations or inspection procedures and to provide the opportunity to comment on such proposals.

The Parties shall notify each other in writing of any changes to Appendix 2.

Article 19

Information relating to quality aspects

The authorities will establish an appropriate means of exchanging information on any confirmed problem reports, corrective actions, recalls, rejected import consignments and other regulatory and enforcement problems for products subject to this Annex.

Article 20

Alert System

The details of an alert system will be developed during the transitional period. The system will be maintained in place at all times. Elements to be considered in developing such a system are described in Appendix 5.

Contact points will be agreed between both Parties to permit authorities to be made aware with the appropriate speed in case of quality defect, recalls, counterfeiting and other problems concerning quality, which could necessitate additional controls or suspension of the distribution of the product.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

For the United States :

Relevant sections of the United States Federal Food, Drug, and Cosmetic Act and the United States Public Health Service Act

Relevant sections of Title 21, United States Code of Federal Regulations (CFR) Parts 1-99, Parts 200-299, Parts 500-599, and Parts 600-799

Relevant sections of the FDA Investigations Operations Manual, the FDA Regulatory Procedures Manual, the FDA Compliance Policy Guidance Manual, the FDA Compliance Program Guidance Manual, and other FDA guidances.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

APPENDIX 1

List of applicable laws, regulations and administrative provisions

For the European Community:

Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products as extended, widened and amended.

Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products as extended, widened and amended.

Council Directive 81/851/EEC of 6 November 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products as widened and amended.

Commission Directive 91/356/EEC of 13 June 1991 laying down the principles and guidelines of good manufacturing practice for medicinal products for human use

Commission Directive 91/412/EEC of 23 July 1991 laying down the principles and guidelines of good manufacturing practice for veterinary medicinal products

Council Regulation No (EEC) 2309/93 of 23 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products

Council Directive 25/92/EEC of 31 March 1992 on the wholesale distribution of medicinal products for human use & Guide to Good Distribution Practice

Current version of the Guide to Good Manufacturing Practice, Rules Governing Medicinal Products in the European Community, Volume IV.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

	Ministero della Sanità, Dipartimento alimenti e nutrizione e sanità pubblica veterinaria - Div. IX, Roma (Veterinary)
Luxembourg:	Direction de la Santé, Division de la Pharmacie et des Médicaments, Luxembourg
The Netherlands:	Staatstoezicht op de Volksgezondheid, Inspectie voor de Gezondheidszorg, Rijswijk
Portugal:	Instituto da Farmácia e do Medicamento (INFARMED), Lisboa
Spain:	Ministerio Sanidad y Consumo, Subdirección. General de Control Farmacéutico, Madrid. (Human) Ministerio de Agricultura Pesca y Alimentación, Madrid, (Veterinary)
Sweden:	Läkemedelsverket (Medical Products Agency), Uppsala.
United Kingdom:	Medicines Control Agency, London. Veterinary Medicines Directorate, Addlestone.
European Union:	European Commission, Brussels. European Agency for the Evaluation of Medicinal Products (EMA), London.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

APPENDIX 2

List of Authorities

United States

In the United States, the regulatory authority is the Food and Drug Administration.

European Community

In the European Community, the regulatory authorities are the following :

Austria:	Bundesministerium Fur Arbeit, Gesundheit, und Soziales, Wien
Belgium:	Ministère van Sociale Zakem, Volksgezondheid en Leefmilieu /Ministere des Affaires Sociales, Sante Publique et Environment/ Algemeine Farmaceutische Inspectie, Inspection Generale de la Pharmacie, Bruxelles,Brussel.
Denmark:	Laegemiddelstryelsen. (Danish Medicines Agency), Brønshøj
Finland:	Laakelaitos/Lakemedelsverket (National Agency for Medicines), Helsinki.
France:	Agence du Médicament, Direction de l'inspection et des établissements, Saint Denis. (Human) Agence Nationale du Médicament Vétérinaire, Fougères (Veterinary)
Germany:	Bundesgesundheitsministerium, Bonn. Paul-Ehrlich Institut, Langen (biologicals only) Zuständige Behörden der 16 Bundesländer: Bayern, Berlin Brandenburg, Bremen, Hamburg, Hessen, Niedersachsen, Nordrhein-Westfalen, Rheinland-Pfalz, Mecklenburg-Vorpommern, Saarland, Sachsen, Sachsenanhatt, Schleswog-Holstein, Thuringen.
Greece:	Ministry of Health and Welfare, National Drug Organisation (E.O.F.), Athens.
Ireland:	Irish Medicines Board, Dublin.
Italy:	Ministero della Sanità, Dipartimento Farmaci e Farmacovigilanza, Roma. (Human)

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

APPENDIX 4

Criteria for Assessing Equivalence for Post- and Pre-Approval

- I. Legal/Regulatory authority and structures and procedures providing for post- and pre-approval:
 - A. Appropriate statutory mandate and jurisdiction.
 - B. Ability to issue and update binding requirements on GMPs and guidance documents.
 - C. Authority to make inspections, review and copy documents, and to take samples and collect other evidence.
 - D. Ability to enforce requirements and to remove products found in violation of such requirements from the market.
 - E. Substantive current good manufacturing requirements.
 - F. Accountability of the regulatory authority.
 - G. Inventory of current products and manufacturers.
 - H. System for maintaining or accessing inspection reports, samples and other analytical data, and other firm/product information relating to matters covered by this Sectoral Annex.

- II. Mechanisms in place to assure appropriate professional standards and avoidance of conflicts of interest.

- III. Administration of the regulatory authority:
 - A. Standards of education/qualification and training.
 - B. Effective quality assurance systems measures to ensure adequate job performance.
 - C. Appropriate staffing and resources to enforce laws and regulations.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

APPENDIX 3

Indicative list of Products covered by the Sectoral Annex

Recognizing that precise definition of medicinal products and drugs are to be found in the legislations referred to above, an indicative list of products covered by the agreement is given below:

- human medicinal products including prescription and non-prescription drugs;
- human biologicals including vaccines, and immunologicals;
- veterinary pharmaceuticals, including prescription and non-prescription drugs, with the exclusion of veterinary immunologicals;
- pre-mixes for the preparation of veterinary medicated feeds (EC), Type A medicated articles for the preparation of veterinary medicated feeds (US);
- intermediate products and active pharmaceutical ingredients or bulk pharmaceuticals(US)/starting materials (EC).

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

VII. Additional specific criteria for pre-approval inspections

- A. Satisfactory demonstration through a jointly developed and administered training program and joint inspections to assess the authorities' capabilities.
- B. Pre-inspection preparation includes the review of appropriate records, including site plans and drug master file or similar documentation to enable adequate inspections.
- C. Ability to verify chemistry, manufacturing and control data supporting an application is authentic and complete.
- D. Ability to assess and evaluate research and development data as scientifically sound, especially transfer technology of pilot, scale up and full scale production batches.
- E. Ability to verify conformity of the on site processes and procedures with those described in the application.
- F. Review and evaluate equipment installation, operational and performance qualification data, and evaluate test method validation.

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

IV. Conduct of Inspections:

- A. Adequate pre-inspection preparation, including appropriate expertise of investigator/team, review of firm/product and databases, and availability of appropriate inspection equipment.**
- B. Adequate conduct of inspection, including statutory access to facilities, effective response to refusals, depth and competence of evaluation of operations, systems, and documentation; collection of evidence; appropriate duration of inspection and completeness of written report of observations to firm management.**
- C. Adequate post-inspection activities, including completeness of inspectors' report, inspection report review where appropriate, and conduct of follow-up inspections and other activities where appropriate, assurance of preservation and retrieval of records .**

V. Execution of regulatory enforcement actions to achieve corrections, designed to prevent future violations, and to remove products found in violation of requirements from the market.

VI. Effective Use of Surveillance Systems:

- A. Sampling and analysis**
- B. Recall monitoring**
- C. Product defect reporting system**
- D. Routine surveillance inspections**
- E. Verification of approved manufacturing process changes to marketing authorizations/approved applications**

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

4. Quality Assurance System

- Pharmacovigilance programme
- Surveillance/monitoring of implementation of corrective action

5. Contact points

For the purpose of this agreement, the contact points for the alert system will be:

for the European Community,

the Executive Director of the European Agency for the Evaluation of Medicinal Products, 7, Westferry Circus, Canary Wharf, UK - London E14 4HB, England.
Telephone +44-171-418 8400, Fax 418 8416.

for the United States :

U.S.-EU MRA - PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) ANNEX

APPENDIX 5

Elements to be Considered in Developing a Two-way Alert System

1. Documentation

- Definition of a crisis/emergency and under what circumstances an alert is required
- Standard Operating Procedures (SOPs)
- Mechanism of health hazards evaluation and classification
- Language of communication and transmission of information

2. Crisis Management System

- Crisis analysis and communication mechanisms
- Establishment of contact points
- Reporting mechanisms

3. Enforcement Procedures

- Follow-up mechanisms
- Corrective action procedures

US - EC MRA Medical Devices Annex

SECTORAL ANNEX ON

MEDICAL DEVICES

PREAMBLE

Recognizing that this Annex constitutes a Sectoral Annex to the Agreement on Mutual Recognition in Relation to Conformity Assessment (Agreement) between the United States (U.S.) and the European Community (EC),

Acknowledging that carrying out the provisions of this Annex will further public health protection, will be an important means of facilitating commerce in medical devices, and will lead to reduced costs for regulators and manufacturers of both Parties,

The Parties agree as follows:

CHAPTER 1

Purpose, Scope, and Coverage of the Sectoral Annex

Article 1

Purpose

1. The purpose of this Annex is to specify the conditions under which a Party will accept

US - EC MRA Medical Devices Annex

UNITED STATES OF AMERICA - EUROPEAN COMMUNITY

MUTUAL RECOGNITION AGREEMENT OF

CONFORMITY ASSESSMENT

SECTORAL ANNEX ON

MEDICAL DEVICES

1. Quality System Evaluations - U.S.-type surveillance/post-market and initial/pre-approval inspection reports and EC-type quality system evaluation reports will be exchanged with regard to all products regulated under both U.S. and EC law as medical devices.
2. Product Evaluation - U.S.-type premarket (510(k)) product evaluation reports and EC-type-testing reports will be exchanged only with regard to those products classified under the U.S. system as Class I/Class II - Tier 2 medical devices which are listed in Appendix 2.
3. Post-Market Vigilance Reports - Post-market vigilance reports will be exchanged with regard to all products regulated under both U.S. and EC law as medical devices.

Additional products and procedures may be made subject to this Annex by agreement of the Parties.

Article 4

Regulatory Authorities

The regulatory authorities shall have the responsibility of implementing the provisions of this Annex, including the designation and monitoring of CABs. Regulatory authorities are specified in Appendix 3. Each Party will promptly notify the other Party in writing of any change in the regulatory authority for a country.

CHAPTER 2 Transition Period

Article 5

Length and purpose of transition period

There will be a three-year transition period immediately following the date of entry into force of the Agreement. During the transition period, the Parties will engage in confidence-building activities for the purpose of obtaining sufficient evidence to make determinations concerning the equivalence of CABs of the other Party with respect to the ability to perform quality system and product evaluations or other reviews resulting in reports to be exchanged under this Annex.

US -EC MRA Medical Devices Annex

the results of quality system-related evaluations and inspections and premarket evaluations of the other Party with regard to medical devices as conducted by listed conformity assessment bodies (CABs) and to provide for other related cooperative activities.

2. This Annex is intended to evolve as programs and policies of the Parties evolve. The Parties will review this Annex periodically, in order to assess progress and identify potential enhancements to this Annex as FDA and EC policies evolve over time.

Article 2

Scope

1. The provisions of this Annex shall apply to the exchange and, where appropriate, endorsement of the following types of reports from CABs assessed to be equivalent:

- a. Under the U.S. system, surveillance/post-market and initial/pre-approval inspection reports;
- b. Under the U.S. system, premarket (510(k)) product evaluation reports;
- c. Under the EC system, quality system evaluation reports; and
- d. Under the EC system, EC type examination and verification reports.

Appendix 1 names the legislation, regulations, and related procedures under which: (a) products are regulated as medical devices by each Party; (b) CABs are designated and confirmed; and (c) these reports are prepared.

2. For purposes of this Annex, equivalence means that: CABs in the EC are capable of conducting product and quality systems evaluations against U.S. regulatory requirements in a manner equivalent to those conducted by FDA; and CABs in the U.S. are capable of conducting product and quality systems evaluations against EC regulatory requirements in a manner equivalent to those conducted by EC CABs.

Article 3

Product Coverage

There are three components to this agreement each covering a discrete range of products:

US-EC Medical Devices Annex

4. Both Parties will exercise good faith efforts to complete the confidence building activities as expeditiously as possible to the extent that the resources of the Parties allow.
5. Both the EC and the U.S. will each prepare annual progress reports which will describe the confidence building activities undertaken during each year of the transition period. The form and content of the reports will be determined by the Parties through the Joint Sectoral Committee.

Article 8

Other transition period activities

1. During the transition period, the Parties will jointly determine the necessary information which must be present in quality system and product evaluation reports.
2. The Parties will jointly develop a notification and alert system to be used in case of defects, recalls, and other problems concerning product quality that could necessitate additional actions (e.g., inspections by the Parties of the importing country) or suspension of the distribution of the product.

CHAPTER 3 **End of transition period**

Article 9

Equivalence Assessment

1. In the final six months of the transition period, the Parties shall proceed to a joint assessment of the equivalence of the CABs that participated in the confidence building activities. CABs will be determined to be equivalent provided they have demonstrated proficiency through the submission of a sufficient number of adequate reports. CABs may be determined to be equivalent with regard to the ability to perform any type of quality system or product evaluation covered by this Annex and with regard to any type of product covered by this Annex. The parties shall develop a list contained in Appendix 5 of CABs determined to be equivalent which shall contain a full explanation of the scope of the equivalency determination, including any appropriate limitations, with regard to performing any type of quality system or product evaluation.
2. The Parties shall allow CABs not listed for participation in the MRA, or listed for

US-EC Medical Devices Annex

Article 6

Listing of CABs

Each Party shall designate CABs to participate in confidence-building activities by transmitting to the other Party a list of CABs which meet the criteria for technical competence and independence, as identified in Appendix 1. The list shall be accompanied by supporting evidence. Designated CABs will be listed in Appendix 4 for participation in the confidence building activities once confirmed by the importing Party. Non-confirmation would have to be justified based on documented evidence.

Article 7

Confidence Building Activities

1. At the beginning of the transitional period, the Joint Sectoral Group will establish a joint confidence building program calculated to provide sufficient evidence of the capabilities of the designated CABs to perform quality system or product evaluations to the specifications of the Parties.
2. The joint confidence building program should include the following actions and activities:
 - a. Seminars designed to inform the Parties and CABs about each Party's regulatory system, procedures, and requirements;
 - b. Workshops designed to provide the Parties with information regarding requirements and procedures for the designation and surveillance of CABs;
 - c. Exchange of information about reports prepared during the transition period;
 - d. Joint training exercises; and
 - e. Observed inspections.
3. During the transition period, any significant problem that is identified with a CAB may be the subject of cooperative activities, as resources allow and as agreed to by the regulatory authorities, aimed at resolving the problem.

US-EC Medical Devices Annex

- a. Full reports of initial quality system evaluations;
 - b. Abbreviated reports of quality systems surveillance audits.
3. If the abbreviated reports do not provide sufficient information, the importing Party may request additional clarification from the CAB.
4. Based on the determination of equivalence in light of the experience gained, the quality system evaluation reports prepared by the CABs listed as equivalent will normally be endorsed by the importing Party, except under specific and delineated circumstances. Examples of such circumstances include indications of material inconsistencies or inadequacies in a report, quality defects identified in post-market surveillance or other specific evidence of serious concern in relation to product quality or consumer safety. In such cases, the importing Party may request clarification from the exporting Party which may lead to a request for re-inspection. The Parties will endeavor to respond to requests for clarification in a timely manner. Where divergence is not clarified in this process, the importing Party may carry out the quality system evaluation.

Article 12

Exchange and endorsement of product evaluation reports

1. EC CABs listed for this purpose will, subject to the specifications and limitations on the list, provide to the FDA 510(k) premarket notification assessment reports prepared to U.S. medical device requirements.
2. U.S. CABs will, subject to the specifications and limitations on the list, provide to the EC notified body of the manufacturer's choice, type examination and verification reports prepared to EC medical device requirements.
3. Based on the determination of equivalence in light of the experience gained, the product evaluation reports prepared by the CABs listed as equivalent will normally be endorsed by the importing Party, except under specific and delineated circumstances. Examples of such circumstances include indications of material inconsistencies, inadequacies, or incompleteness in a product evaluation report, or other specific evidence of serious concern in relation to product safety, performance, or quality. In such cases, the importing Party may request clarification from the exporting Party which may lead to a request for a re-evaluation. The parties will endeavor to respond to requests for clarification in a timely

US-EC Medical Devices Annex

participation only as to certain types of evaluations, to apply for participation in this MRA once the necessary measures have been taken or sufficient experience has been gained, in accordance with Article 18.

3. Decisions concerning the equivalence of CABs must be agreed to by both Parties.

CHAPTER 4 Operational Period

Article 10

Start of the operational period

1. The operational period will start at the end of the transition period after the Parties have developed the list of CABs found to be equivalent. The provisions of this Chapter will apply only with regard to listed CABs and only to the extent of any specifications and limitations contained on the list with regard to a CAB.

2. The operational period will apply to quality system evaluation reports and product evaluation reports generated by CABs listed in accordance with this Annex for the evaluations performed in the respective territories of the Parties, except if the Parties agree otherwise.

Article 11

Exchange and endorsement of quality system evaluation reports

1. Listed EC CABs will provide FDA with reports of quality system evaluations, as follows:

- a. For pre-approval quality system evaluations, EC CABs will provide full reports; and
- b. For surveillance quality system evaluations, EC CABs will provide abbreviated reports.

2. Listed U.S. CABs will provide to the EC Notified Body of the manufacturer's choice:

US-EC Medical Devices Annex

3. Following such annual designations, the procedures for confirmation of CABs under Articles 7(c) and (d) of the Agreement shall apply.

CHAPTER 5 Joint Sectoral Committee

Article 17

Role and composition of the Joint Sectoral Committee

1. A Joint Sectoral Management Committee is set up to monitor the activities under both the transitional and operational phases of this Annex.
2. The Committee will be co-chaired by a representative of the FDA for the U.S. and a representative of the EC who will each have one vote. Decisions will be taken by unanimous consent.
3. The JSC's functions will include:
 - a. making a joint assessment of the equivalence of CABs;
 - b. developing and maintaining the list of equivalent CABs, including any limitation in terms of their scope of activities and communicating the list to all authorities and the Joint Committee;
 - c. providing a forum to discuss issues relating to this Annex, including concerns that a CAB may no longer be equivalent and opportunity to review product coverage; and
 - d. consideration of the issue of suspension.

US-EC Medical Devices Annex

manner. Endorsement remains the responsibility of the importing Party.

Article 13

Transmission of quality system evaluation reports

Quality system evaluation reports covered by Article 11 concerning products covered by this Annex shall be transmitted to the importing Party within 60 calendar days of a request by the importing Party. Should a new inspection be requested the time period shall be extended by an additional 30 calendar days. A Party may request a new inspection, for cause, identified to the other Party. If the exporting Party cannot perform an inspection within a specified period of time, the importing Party may perform an inspection on its own.

Article 14

Transmission of product evaluation reports

Transmission of product evaluation reports will take place according to the importing Party's specified procedures.

Article 15

Monitoring continued equivalence

Monitoring activities will be carried out in accordance with Article 10 of the Agreement.

Article 16

Listing of Additional CABs

1. During the operational phase, additional CABs will be considered for equivalence using the procedures and criteria described in Articles 6, 7, and 9 of this Annex, taking into account the level of confidence gained in the overall regulatory system of the other Party.

2. Once a designating authority considers that such CABs, having undergone the procedures of Articles 6, 7, and 9 of this Annex, may be determined to be equivalent, it will then designate those bodies on an annual basis. Such procedures satisfy the procedures of Article 7(a) and (b) of the Agreement.

US-EC Medical Devices Annex

US-EC Medical Devices Annex

CHAPTER 6 Harmonization and Information Exchange

Article 18

Harmonization

During both the transitional and operational phases of this Agreement, both Parties intend to continue to participate in the activities of the Global Harmonization Task Force and utilize the results of those activities to the extent possible. Such participation involves developing and reviewing documents developed by the Global Harmonization Task Force and jointly determining whether they are applicable to the implementation of this Agreement.

Article 19

Regulatory cooperation

The Parties and authorities shall inform and consult with one another, as permitted by law, of proposals to introduce new controls or to change existing technical regulations or inspection procedures and to provide the opportunity to comment on such proposals.

The Parties shall notify each other in writing of any changes to Appendix 1.

Article 20

Alert system and exchange of post-market vigilance reports

1. An alert system will be set up during the transition period and maintained thereafter by which the Parties will notify each other when there is an immediate danger to public health. Elements of such a system will be described in an Appendix to be attached to this Sectoral Annex. As part of that system, each Party shall notify the other Party of any confirmed problem reports, corrective actions, or recalls. These reports are regarded as part of ongoing investigations.

2. Contact points will be agreed between both Parties to permit authorities to be made aware with the appropriate speed in case of quality defect, batch recalls, counterfeiting and other problems concerning quality, which could necessitate additional controls or suspension of the distribution of the product.

US-EC Medical Devices Annex

APPENDIX 2 Scope of Product Coverage

1. Initial Coverage of the Transition Period

Upon entry into force of this Annex,¹ products qualifying for the transitional arrangements under this Agreement include:

- a. All Class I products requiring premarket evaluations in the United States - see Table 1.
- b. Those Class II products listed in Table 2.

2. During the Transition Period

The Parties will jointly identify additional product groups, including their related accessories, in line with their respective priorities as follows:

- a. Those for which review may be based primarily on written guidance which the Parties will use their best efforts to prepare expeditiously; and
- b. Those for which review may be based primarily on international standards, in order for the Parties to gain the requisite experience.

The corresponding additional product lists will be phased in on an annual basis. The Parties may consult with industry and other interested Parties in determining which products will be added.

¹ It is understood that the date of entry into force will not occur prior to June 1, 1998 unless the Parties decide otherwise.

US-EC Medical Devices Annex

APPENDIX 1 Relevant Legislation, Regulations and Procedures

1. For the European Union the following legislation applies to Article 2 paragraph 1:
 - a. Council Directive 901385/EEC of 20 June 1990 on active implantable medical devices -OJ No. L 189, 20.7. 1990, p. 17. Conformity assessment procedures.
 - *Annex 2 (with the exception of section 4)
 - *Annex 4
 - *Annex 5
 - b. Council Directive 93142/EEC of 14 June 1993 on Medical Devices OJ No. L 169,12.7.1993, p.1. Conformity assessment procedures.
 - *Annex 2 (with the exception of section 4)
 - *Annex 3
 - *Annex 4
 - *Annex 5
 - *Annex 6
2. For the United States, the following legislation applies to Article 2 paragraph 1:
 - a. The Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 321 et seq.
 - b. The Public Health Service Act, 42 U.S.C. §§ 201 et seq.
 - c. Regulations of the United States Food and Drug Administration found at 21 C.F.R., in particular, Parts 800 to 1299.
 - d. Medical Devices; Third-Party Review of Selected Premarket Notifications; Pilot Program, 61 Fed. Reg. 14,789-14.796 (April 3, 1996).

TABLE 1

**CLASS I PRODUCTS REQUIRING PREMARKET EVALUATIONS
IN THE UNITED STATES, INCLUDED IN SCOPE OF PRODUCT COVERAGE AT BEGINNING
OF TRANSITION PERIOD**

US-EC Medical Devices Annex

3. Commencement of the Operational Period

a. At the commencement of the operational period, product coverage shall extend to all Class I/II products covered during the transition period.

b. FDA will expand the program to categories of Class II devices as is consistent with the results of the pilot, and with the FDA's ability to write guidance documents if the device pilot for the third party review of medical devices is successful. The MRA will cover to the maximum extent feasible all Class II devices listed in Table 3 for which FDA-accredited third-party review is available in the U.S..

4. Unless explicitly included by joint decision of the Parties, this agreement does not cover any U.S. Class II -tier 3 or any Class III product under either system.

US -EC MIRA Medical Devices Annex

Table 1

868.6810

TRACHEOBRONCHIAL SUCTION CATHETER
BSY - CATHETERS, SUCTION, TRACHEOBRONCHIAL

TABLE 1: CLASS I PRODUCTS REQUIRING PREMARKET EVALUATIONS IN THE UNITED STATES

ANESTHESIOLOGY PANEL (868)

Section No.	Regulation Name	Product Code - Device Name
868.1910	ESOPHAGEAL STETHOSCOPE BZW - STETHOSCOPE, ESOPHAGEAL	
868.5620	BREATHING MOUTHPIECE BYP - MOUTHPIECE, BREATHING	
868.5640	MEDICINAL NONVENTILATORY NEBULIZER (ATOMIZER) CCQ - NEBULIZER, MEDICINAL, NON-VENTILATORY (ATOMIZER)	
868.5675	REBREATHING DEVICE BYW - DEVICE, REBREATHING	
868.5700	NONPOWERED OXYGEN TENT FOG - HOOD, OXYGEN, INFANT BYL - TENT, OXYGEN	

US -EC MRÀ Medical Devices Annex
Table 1

CARDIOVASCULAR PANEL

Section No.	Regulation Name Product Code - Device Name
*****	*****
(NONE)	

DENTAL PANEL (872)

Section No.	Regulation Name Product Code - Device Name
*****	*****
872.3400	KARAYA AND SODIUM BORATE WITH OR WITHOUT ACACIA DENTURE ADHESIVE KOM - ADHESIVE, DENTURE, ACACIA AND KARAYA WITH SODIUM BORATE
872.3700	DENTAL MERCURY (U.S.P) ELY - MERCURY
872.4200	DENTAL HANDPIECES AND ACCESSORIES EBW - CONTROLLER, FOOD, HANDPIECE AND CORD EFB - HANDPIECE, AIR-POWERED, DENTAL EFA - HANDPIECE, BELT AND/OR GEAR DRIVEN, DENTAL EGS - HANDPIECE, CONTRA- AND RIGHT-ANGLE ATTACHMENT, DENTAL EKX - HANDPIECE, DIRECT DRIVE, AC-POWERED EKY - HANDPIECE, WATER-POWERED
872.6640	DENTAL OPERATIVE UNIT EIA - UNIT, OPERATIVE DENTAL

US - FCC NIRA Medical Devices Annex
Table 1

874.5550	POWERED NASAL IRRIGATOR KNA - IRRIGATOR, POWERED NASAL
----------	---

EAR, NOSE, AND THROAT PANEL (874)

Section No.	Regulation Name Product Code - Device Name
*****	*****
874.1070	SHORT INCREMENT SENSITIVITY INDEX (SISI) ADAPTER ER - ADAPTER, SHORT INCREMENT SENSITIVITY INDEX (SISI)
874.1500	CUSTOMETER ETM - CUSTOMETER
874.1800	AIR OR WATER CALORIC STIMULATOR KIH - STIMULATOR, CALORIC-AIR IEP - STIMULATOR, CALORIC-WATER
874.1925	TOYNBEE DIAGNOSTIC TUBE ETR - TUBE, TOYNBEE DIAGNOSTIC
874.3300	HEARING AID LRB - FACE PLATE HEARING-AID ISD - HEARING-AID, AIR-CONDUCTION
874.4100	EPISTAXIS BALLOON EMX - BALLOON, EPISTAXIS
874.5300	ENT EXAMINATION AND TREATMENT UNIT ETF - UNIT, EXAMINING/TREATMENT, ENT

880.5420 PRESSURE INFUSOR FOR I.V. BAG
KZD - INFUSOR, PRESSURE, FOR I.V. BAGS

880.5680 PEDIATRIC POSITION HOLDER
FRP - HOLDER, INFANT POSITION

880.6250 PATIENT EXAMINATION GLOVE
LZB - FINGER COT

FMC - GLOVE, PATIENT EXAMINATION
LYY - GLOVE, PATIENT EXAMINATION, LATEX
LZA - GLOVE, PATIENT EXAMINATION, POLY
LZC - GLOVE, PATIENT EXAMINATION, SPECIALTY
LYZ - GLOVE, PATIENT EXAMINATION, VINYL

880.6375 PATIENT FLBRICANT
KMB - FLBRICANT, PATIENT

880.6760 PROTECTIVE RESTRAINT
BRT - RESTRAINT, PATIENT, CONDUCTIVE
FMQ - RESTRAINT, PROTECTIVE

NEUROLOGY PANEL (882)

Section No.
Regulation Name
Product Code - Device Name

882.1030 ATAXIAGRAPH
GWW - ATAXIAGRAPH

Section No.	Regulation Name	Product Code - Device Name
8745840	ANTISTAMMERING DEVICE	ANTI-STAMMERING KIT - DEVICE, ANTI-STAMMERING
GASTROENTEROLOGY - UROLOGY PANEL (876)		
8765160	UROLOGICAL CLAMPS FOR MALES	UUA - CLAMP, PENILE
8765210	ENEMA KIT	ICE - KIT, ENEMA (FOR CLEANING PURPOSE)
8765250	URINE COLLECTOR AND ACCESSORIES	UAG - BAG, URINE COLLECTION, EBG, FOR EXTERNAL USE
GENERAL HOSPITAL PANEL (880)		
8805270	NEONATAL EYE PAD	NEONATAL EYE PAD FOK - PAD, NEONATAL EYE

US - FDA MIRA Medical Devices Annex
Table 1

882.1420	ELECTROENCEPHALOGRAM (EEG) SIGNAL SPECTRUM ANALYZER GWS - ANALYZER, SPECTRUM, ELECTROENCEPHALOGRAM SIGNAL
882.4060	VENTRICULAR CANNULA ICD - CANNULA, VENTRICULAR

ORTHOPEDIC PANEL (888)

Section No.	Regulation Name	Product Code - Device Name
888.1500	AC-POWERED GONIOMETER	KQX - GONIOMETER, AC-POWERED
888.4150	CALIPERS FOR CLINICAL USE	KTZ - CALIPER

PHYSICAL MEDICINE PANEL (890)

Section No.	Regulation Name	Product Code - Device Name
890.3850	MECHANICAL WHEELCHAIR	LBE - STROLLER, ADAPTIVE IOR - WHEELCHAIR, MECHANICAL
890.5180	MANUAL PATIENT ROTATION BED	INY - BED, PATIENT ROTATION, MANUAL.
890.5710	HOT OR COLD DISPOSABLE PACK	IMD - PACK, HOT OR COLD, DISPOSABLE

OPHTHALMOLOGY PANEL (886)

Section No.	Regulation Name	Product Code - Device Name
886.1780	RETINOSCOPE	HKM - RETINOSCOPE, BATTERY-POWERED
886.1940	TONOMETER STERILIZER	HKZ - STERILIZER, TONOMETER
886.1070	POWERED CORNEAL BURR	HOQ - BURR, CORNEAL, AC-POWERED HOG - BURR, CORNEAL, BATTERY-POWERED HIRG - ENGINE, TREPHINE, ACCESSORIES, AC-POWERED HIR - ENGINE, TREPHINE, ACCESSORIES, BATTERY-POWERED HLD - ENGINE, TREPHINE, ACCESSORIES, GAS-POWERED
886.4300	KERATOME	HNQ - KERATOME, AC-POWERED HMY - KERATOME, BATTERY-POWERED
886.5850	SUNGLASSES (NON-PRESCRIPTION)	HQY - SUNGLASSES (NON-PRESCRIPTION INCLUDING PHOTOSENSITIVE)

RADIOLOGY PANEL (892)

Section	No.	Regulation Name	Product Code - Device Name
*****	*****	*****	*****

892.1100 SCINTILLATION GAMMA CAMERA
 IYX - CAMERA, SCINTILLATION (GAMMA)

892.1110 POSTRON CAMERA
 IZC - CAMERA, POSTRON

892.1300 NUCLEAR RECTILINEAR SCANNER
 IYW - SCANNER, RECTILINEAR, NUCLEAR

892.1320 NUCLEAR UPTAKE PROBE
 IZD - PROBE, UPTAKE, NUCLEAR

892.1330 NUCLEAR WHOLE BODY SCANNER
 IJM - SCANNER, WHOLE BODY, NUCLEAR

892.1410 NUCLEAR ELECTROCARDIOGRAPH SYNCHRONIZER
 IYV - SYNCHRONIZER, ELECTROCARDIOGRAPH, NUCLEAR

892.1890 RADIOGRAPHIC-FILM ILLUMINATOR
 IXC - ILLUMINATOR, RADIOGRAPHIC-FILM
 IJG - ILLUMINATOR, RADIOGRAPHIC-FILM, EXPLOSION-PROOF

892.1910 RADIOGRAPHIC GRID

**US - EC MRA Medical Devices Annex
Table 1**

US - FCC NIRA Medical Devices Annex
Table 1

892.1960 RADIOGRAPHIC INTENSIFYING SCREEN
WAM - SCREEN, INTENSIFYING, RADIOGRAPHIC

892.1970 RADIOGRAPHIC ECG/RESPIRATOR SYNCHRONIZER
IXO - SYNCHRONIZER, ECG/RESPIRATOR, RADIOGRAPHIC

892.5650 MANUAL RADIONUCLIDE APPLICATOR SYSTEM
IWG - SYSTEM, APPLICATOR, RADIONUCLIDE, MANUAL.

GENERAL AND PLASTIC SURGERY PANEL (878)

Section No.	Regulation Name	Product Code - Device Name
878.1200	INTRODUCTION/DRAINAGE CATHETER AND ACCESSORIES	
	KGZ - ACCESSORIES, CATHETER	
	GCE - ADAPTOR, CATHETER	
	FGY - CANNULA, INJECTION	
	GBA - CATHETER, BALLOON TYPE	
	GBZ - CATHETER, CHOLANGIOGRAPHY	
	GBQ - CATHETER, CONTINUOUS IRRIGATION	
	GBY - CATHETER, EUSTACHIAN, GENERAL & PLASTIC SURGERY	
	JCY - CATHETER, INFUSION	
	GBX - CATHETER, IRRIGATION	
	GBP - CATHETER, MULTIPLE LUMEN	
	GBO - CATHETER, NEPHROSTOMY, GENERAL & PLASTIC SURGERY	
	GBN - CATHETER, PEDIATRIC, GENERAL & PLASTIC SURGERY	
	GBW - CATHETER, PERITONEAL	
	GBS - CATHETER, VENTRICULAR, GENERAL & PLASTIC SURGERY	

IXJ-GRID, RADIOGRAPHIC

Section	Regulation Name	Product Code - Device Name
878.4320	REMOVABLE SKIN CLIP	FZQ - CLIP, REMOVABLE (SKIN)
878.4460	SURGEON'S GLOVES	KGO - SURGEON'S GLOVES
878.4680	NONPOWERED, SINGLE PATIENT, PORTABLE SUCTION APPARATUS	GCY - APPARATUS, SUCTION, SINGLE PATIENT USE, PORTABLE, NONPOWERED
878.4760	REMOVABLE SKIN STAPLE	GDT - STAPLE, REMOVABLE (SKIN)
GENERAL AND PLASTIC SURGERY PANEL (878) (CONTINUED)		
878.4820	AC-POWERED, BATTERY-POWERED, AND PNEUMATICALLY POWERED SURGICAL INSTRUMENT MOTOR	GFG - BIT, SURGICAL GFA - BLADE, SAW, GENERAL & PLASTIC SURGERY DWH - BLADE, SAW, SURGICAL, CARDIOVASCULAR BRZ - BOARD, ARM (WITH COVER) GFE - BRUSH, DERMABRASION GFF - BUR, SURGICAL, GENERAL & PLASTIC SURGERY

US - ECG MIRA Medical Devices Annex
Table 1

GCD - CONNECTOR, CATHETER
GCC - DILATOR, CATHETER
GCB - NEEDLE, CATHETER

US-EC MIRA Medical Devices Annex
Table 1

878.4960	GFB - HEAD, SURGICAL, HAMMER GEY - MOTOR, SURGICAL INSTRUMENT, AC-POWERED GET - MOTOR, SURGICAL INSTRUMENT, PNEUMATIC POWERED DWI - SAW, ELECTRICALLY POWERED KFK - SAW, PNEUMATICALLY POWERED HAB - SAW, POWERED, AND ACCESSORIES AIR OR AC-POWERED OPERATING TABLE AND AIR OR AC-POWERED OPERATING CHAIR & ACCESSORIES
880.5090	GBB - CHAIR, SURGICAL, AC-POWERED FQO - TABLE, OPERATING-ROOM, AC-POWERED GDC - TABLE, OPERATING-ROOM, ELECTRICAL FVW - TABLE, OPERATING-ROOM, PNEUMATIC JFA - TABLE, SURGICAL WITH ORTHOPEDIC ACCESSORIES, AC-POWERED LIQUID BANDAGE KMF - BANDAGE, LIQUID

**US -ECG MIRA Medical Devices Annex
Table 1**

**KIDG - CHISEL (OSTEOTOME)
GFD - DERMATOME
GFC - DRIVER, SURGICAL, PIN**

SECTION	NO	REGULATION NAME	PRODUCT CODE - DEVICE NAME
	892 1000	MAGNETIC RESONANCE DIAGNOSTIC DEVICE	MOS - COIL, MAGNETIC RESONANCE, SPECIALTY MRI - SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING MRI - SYSTEM, NUCLEAR MAGNETIC RESONANCE SPECTROSCOPIC
	892 1510	NONETAL ULTRASONIC MONITOR	IAE - MONITOR, ULTRASONIC, NONETAL
	892 1550	ULTRASONIC PULSED DOPPLER IMAGING SYSTEM	ULN - SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC
	892 1560	ULTRASONIC PULSED ECHO IMAGING SYSTEM	IYO - SYSTEM, IMAGING, PULSED ECHO, ULTRASONIC
	892 1570	DIAGNOSTIC ULTRASONIC TRANSDUCER	ITX - TRANSDUCER, ULTRASONIC, DIAGNOSTIC
	892 1600	ANGIOGRAPHIC X-RAY SYSTEM	ANGIOGRAPHIC X-RAY SYSTEM IZI - SYSTEM, X-RAY, ANGIOGRAPHIC
	892 1680	STATIONARY X-RAY SYSTEM	STATIONARY X-RAY SYSTEM NPR - SYSTEM, X-RAY, STATIONARY
	892 1720	MOBILE X-RAY SYSTEM	MOBILE X-RAY SYSTEM IZI - SYSTEM, X-RAY, MOBILE
	892 1710	TOMOGRAPHIC X-RAY SYSTEM	TOMOGRAPHIC X-RAY SYSTEM IZE - SYSTEM, X-RAY, TOMOGRAPHIC
	892 1750	COMPUTED TOMOGRAPHY X-RAY SYSTEM	COMPUTED TOMOGRAPHY X-RAY SYSTEM IAK - SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED
Related Devices:	870 2340	ELECTROCARDIOGRAPH	ELECTROCARDIOGRAPH DPS - ELECTROCARDIOGRAPH MLC - MONITOR, ST SEGMENT
	870 2350	ELECTROCARDIOGRAPH LEAD SWITCHING ADAPTOR	ELECTROCARDIOGRAPH LEAD SWITCHING ADAPTOR

TABLE 2

**CLASS II MEDICAL DEVICES INCLUDED
IN SCOPE OF PRODUCT COVERAGE
AT BEGINNING OF TRANSITION PERIOD**

U.S. to develop guidance documents identifying U.S. requirements and EC to identify standards needed to meet EC requirements

US-ECG MIRA Medical Devices Annex
Table 2

P/N/EI	SEQ. ION NO	REGULATION NAME PRODUCT CODE - DEVICE NAME
		110C - UNIT, PHACORAGGMENTATION
SD	878 1580	SURGICAL LAMP 111 - ILLUMINATOR, FIBEROPTIC, SURGICAL FIELD 112 - ILLUMINATOR, NON-REMOTE 113 - ILLUMINATOR, REMOTE 114 - LAMP, FLUORESCEN, AC-POWERED 115 - LAMP, OPERATING-ROOM 116 - LAMP, SURGICAL 117 - LAMP, SURGICAL, INCANDESCENT 118 - LIGHT, SURGICAL, ACCESSORIES 119 - LIGHT, SURGICAL, CARRIER 120 - LIGHT, SURGICAL, CEILING MOUNTED 121 - LIGHT, SURGICAL, CONNECTOR 122 - LIGHT, SURGICAL, ENDOSCOPIC 123 - LIGHT, SURGICAL, FIBEROPTIC 124 - LIGHT, SURGICAL, FLOOR STANDING 125 - LIGHT, SURGICAL, INSTRUMENT
FI	882 5890	TRANS CUTANEOUS ELECTRICAL NERVE STIMULATOR FOR PAIN RELIEF 671 - STIMULATOR, NERVE, TRANSDUCERS, FOR PAIN RELIEF
Noninvasive Blood Pressure Measurement Devices:		
CV	870 1120	BLOOD PRESSURE CUFF DXQ - CUFF, BLOOD-PRESSURE
CV	870 1130	NONINVASIVE BLOOD PRESSURE MEASUREMENT SYSTEM (except non-oscillometric) DXN - SYSTEM, MEASUREMENT, BLOOD-PRESSURE, NON-INVASIVE
HO	880 6880	STEAM STERILIZER (greater than 2 cubic feet) EIE - STERILIZER, STEAM
Clinical Thermometers:		
HO	880 2910	CLINICAL ELECTRONIC THERMOMETER (except tympanic or pacifier) EIL - THERMOMETER, ELECTRONIC, CLINICAL

PANEL	SECTION NO	REGISTRATION NAME	PRODUCT CODE - DEVICE NAME
		DRW - ADAPTOR, LEAD SWITCHING, ELECTROCARDIOGRAPH	
CV	870 2360	ELECTROCARDIOGRAPH ELECTRODE DRX - ELECTRODE, ELECTROCARDIOGRAPH	
CV	870 2570	111 - ELECTROCARDIOGRAPH SURFACE ELECTRODE TESTER KRC - TESTER, ELECTRODE, SURFACE, ELECTROCARDIOGRAPHIC	
NI	882 1100	111 - ELECTROENCEPHALOGRAPH GWQ - ELECTROENCEPHALOGRAPH	
HO	880 5725	INFUSION PUMP (external only) MRZ - ACCESSORIES, PUMP, INFUSION LRN - PUMP INFUSION LZE - PUMP INFUSION ANALYTICAL SAMPLING MFB - PUMP INFUSION ELASTOMERIC LZH - PUMP INFUSION ENTERAL MHD - PUMP INFUSION GASTRO DISSOLUTION LZG - PUMP INFUSION INSULIN MVA - PUMP INFUSION PCA	
Ophthalmic Instruments			
OP	886 1570	OPHTHALMOSCOPE H11 - OPHTHALMOSCOPE, AC-POWERED H1J - OPHTHALMOSCOPE, BATTERY-POWERED	
OP	886 1780	RETINOSCOPE H11 - RETINOSCOPE, AC-POWERED	
OP	886 1850	AC-POWERED SLIT-LAMP BIOMICROSCOPE H10 - BIOMICROSCOPE, SLIT-LAMP, AC-POWERED	
OP	886 4150	VITREOUS ASPIRATION AND CUTTING INSTRUMENT MMG - DILATOR, EXPANSIVE IRIS (ACCESSORY) HOE - INSTRUMENT, VITREOUS ASPIRATION AND CUTTING, AC-POWERED HKP - INSTRUMENT, VITREOUS ASPIRATION AND CUTTING, BATTERY-POWERED MIZ - VITRECTOMY, INSTRUMENT CUTTER	
OP	886 4670	PHACOLYTIC IRRIGATION SYSTEM	

SECTION NO.	REGULATION NAME	PRODUCT CODE - DEVICE NAME
	EMA - GENERAL DENTAL	EMB - ZINC OXIDE EUGENOL
872 3660	IMPRESSION MATERIAL	IMP - MATERIAL, IMPRESSION
872 3690	TOOTH SHADE RESIN MATERIAL	TSH - MATERIAL, TOOTH SHADE, RESIN
872 3710	BASE METAL ALLOY	BM - METAL, BASE
881 3300		CORONAL

odontom

US-EC MIRA Medical Devices Annex
Table 2

PANEL	SECTION NO	REGULATION NAME PRODUCT CODE - DEVICE NAME
AN	868 5630	NEBU LIZER CAF - NEBU LIZER (DIRECT PATIENT INTERFACE)
AN	868 5925	POWERED EMERGENCY VENTILATOR
Hydraulic Needles and Syringes (except anti-stick and self-destruct)		
HO	880 5570	HYPODERMIC SINGLE LUMEN NEEDLE AMK - CONTAINER, SHARPS FMJ - NEEDLE, HYPODERMIC, SINGLE LUMEN MHC - PORT, INTRAOSSEOUS, IMPLANTED
HO	880 5869	PISTON SYRINGE IAM - SYRINGE, PISTON
OR	888 6020	INTRAMEDULLARY FIXATION ROD HSH - ROD, FIXATION, INTRAMEDULLARY AND ACCESSORIES
Manual Fixators (except devices with no external components)		
OR	888 6030	SINGLE AND DUAL COMPONENT METALLIC BONE FIXATION APPLIANCES & ACCESSORIES NLT - APPLIANCE, FIXATION, NAIL/BI ADIPLATE COMBINATION, MULTIPLE COMPONENT
OR	888 3040	SMOOTH OR THREADED METALLIC BONE FIXATION FASTENER JEC - COMPONENT, TRACTION, INVASIVE LTY - PIN, FIXATION, SMOOTH JDW - PIN, FIXATION, THREADED
Selected Dental Materials:		
DE	872 3060	(GOLD) BASED ALLOYS AND PRECIOUS METAL ALLOYS FOR CLINICAL USE EJT - ALLOY, GOLD BASED, FOR CLINICAL USE EIS - ALLOY, PRECIOUS METAL, FOR CLINICAL USE
DE	872 3200	RESIN TOOTH BONDING AGENT KLE - AGENT, TOOTH BONDING, RESIN
DE	872 3275	DENTAL CEMENT

U.S.-EC MRA Medical Devices Annex
Table 3

Physiology Panel

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

anesthesia services	868 5160	Gas machine for anesthesia or analgesia	2
	868 5270	Breathing system heater	2
	868 5440	Portable oxygen generator	2
	868 5450	Respiratory gas humidifier	2
	868 5630	Nebulizer	2
	868 5710	Electrically powered oxygen tent	2
	868 5880	Anesthetic vaporizer	2

Gas Analyzer	868 1610	Powered Algesimeter	2
	868 1075	Argon gas analyzer	2
	868 1400	Carbon dioxide gas analyzer	2
	868 1430	Carbon monoxide gas analyzer	2
	868 1500	Enflurane gas analyzer	2
	868 1620	Halothane gas analyzer	2
	868 1640	Helium gas analyzer	2
	868 1670	Neon gas analyzer	2
	868 1690	Nitrogen gas analyzer	2
	868 1700	Nitrous oxide gas analyzer	2
	868 1720	Oxygen gas analyzer	2
	868 1730	Oxygen uptake computer	2
Peripheral Nerve Stimulators	868 2775	Electrical peripheral nerve stimulator	2

**U.S.-ECG MIRA Medical Devices Annex
Table 3**

**MEDICAL DEVICES FOR POSSIBLE INCLUSION
IN SCOPE OF PRODUCT COVERAGE
DURING OPERATIONAL PERIOD**

TABLE 3

**U.S.-ECG MIRA Medical Devices Annex
Table 3**

868.5955	Intermittent mandatory ventilation attachment	2
868.6250	Portable air compressor	2

Cardiovascular Panel

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

Cardiovascular Diagnostic	870.1125	Programmable diagnostic computer	2
	870.1450	Densitometer	2
	870.2310	Apex cardiograph (vibracardiograph)	2
	870.2320	Bedside cardiograph	2
	870.2340	Electrocardiograph	2
	870.2356	Electrocardiograph lead switching adaptor	1
	870.2360	Electrocardiograph electrode	2
	870.2370	Electrocardiograph surface electrode tester	2
	870.2400	Vectorcardiograph	1
	870.2450	Medical cathode-ray tube display	1
	870.2675	Oscilloscope	2
	870.2840	Apex cardiographic transducer	2
	870.2860	Heart sound transducer	2

Cardiovascular Monitoring		Valve, pressure relief, cardiopulmonary bypass	
	870.1100	Blood pressure alarm	2
	870.1110	Blood pressure computer	2
	870.1120	Blood pressure cuff	2

**U.S.-EC MIRA Medical Devices Annex
Table 3**

Respiratory Monitoring	868 1750	Pressure plethysmograph	2
	868 1760	Volume plethysmograph	2
	868 1780	Inspiratory airway pressure meter	2
	868 1800	Rhinomanometer	2
	868 1810	Diagnostic spirometer	2
	868 1850	Monitoring spirometer	2
	868 1860	Peak-flow meter for spirometry	2
	868 1880	Pulmonary-function data calculator	2
	868 1890	Predictive pulmonary-function value calculator	2
	868 1900	Diagnostic pulmonary-function interpretation calculator	2
	868 2025	Ultrasonic air embolism monitor	2
	868 2375	Breathing frequency monitor (except apnea detectors)	2
	868 2480	Transcutaneous carbon dioxide (PtcO ₂) monitor	2
	868 2500	Transcutaneous oxygen monitor (for an infant not under gas anesthesia)	2
	868 2550	Pneumotachometer	2
	868 2600	Airway pressure monitor	2
	868 5665	Powered percussor	2
	868 5690	Incentive spirometer	2
Ventilator	868 5905	Noncontinuous ventilator (IPPB)	2
	868 5925	Powered emergency ventilator	2
	868 5935	External negative pressure ventilator	2
	868 5895	Continuous ventilator	2

**U.S.-EC NIRA Medical Devices Annex
Table 3**

	870 4205	Cardiopulmonary bypass bubble detector	2
	870 4220	Cardiopulmonary bypass heart-lung machine console	2
	870 4240	Cardiovascular bypass heat exchanger	2
	870 4250	Cardiopulmonary bypass temperature controller	2
	870 4300	Cardiopulmonary bypass gas control unit	2
	870 4310	Cardiopulmonary bypass coronary pressure gauge	2
	870 4330	Cardiopulmonary bypass on-line blood gas monitor	2
	870 4340	Cardiopulmonary bypass level sensing monitor and/or control	2
	870 4370	Roller-type cardiopulmonary bypass blood pump	2
	870 4380	Cardiopulmonary bypass pump speed control	2
	870 4410	Cardiopulmonary bypass in-line blood gas sensor	2
Cardiovascular Therapeutic	870 5050	Patent cure suction apparatus	2
	870 5000	Thermal regulation system	2
Defibrillator	870 5300	DC-defibrillator (including paddles)	2
	870 5325	Defibrillator tester	2
Echocardiograph	870 2330	Echocardiograph	2
Pacemaker & Accessories	870 1750	External programmable pacemaker pulse generator	2
	870 3630	Pacemaker generator function analyzer	2
	870 3640	Indirect pacemaker generator function analyzer	2
	870 3720	Pacemaker electrode function tester	2

U.S.-ECU MIRA Medical Devices Annex
Table 3

870 1130	Noninvasive blood pressure measurement system	2
870 1140	Venous blood pressure manometer	2
870 1220	Electrode recording catheter or electrode recording probe	2
870 1270	Intracavitary phonocatheter system	2
870 1875	Stethoscope (electronic)	2
870 2050	Biopotential amplifier and signal conditioner	2
870 2060	Transducer signal amplifier and conditioner	2
870 2100	Cardiovascular blood flow-meter	2
870 2120	Extravascular blood flow probe	2
870 2300	Cardiac monitor (including cardiachometer and rate alarm)	2
870 2700	Osmometer	2
870 2710	Leak oscillator	2
870 2750	Impedance plethmograph	2
870 2770	Impedance plethysmograph	2
870 2780	Hydraulic, pneumatic, or photoelectric plethysmographs	2
870 2850	Extravascular blood pressure transducer	2
870 2870	Catheter tip pressure transducer	2
870 2880	Ultrasonic transducer	2
870 2890	Vessel occlusion transducer	2
870 2900	Patient transducer and electrode cable (including connector)	2
870 2910	Radiofrequency physiological signal transmitter and receiver	2
870 2920	Telephone electrocardiograph transmitter and receiver	2

**U.S.-ECF MRA Medical Devices Annex
Table 3**

	872.3300	Hydrophilic resin coating for dentures	2
	872.3310	Coating material for resin fillings	2
	872.3590	Preformed plastic denture tooth	2
	872.3660	Impression material	2
	872.3690	Tooth shade resin material	2
	872.3710	Base metal alloy	2
	872.3750	Bracket adhesive resin and tooth conditioner	2
	872.3760	Denture relining, repairing, or rebasing resin	2
	872.3765	Pit and fissure sealant and conditioner	2
	872.3770	Temporary crown and bridge resin	2
	872.3820	Root canal filling resin (other than chloroform use)	2
	872.3920	Porcelain tooth	2

Dental X-ray	872.1800	Extraoral source x-ray system	2
	872.1810	Intraoral source x-ray system	2

Dental Implants	872.4880	Intraosseous fixation screw or wires	2
	872.3890	Endodontic stabilizing splint	2

Orthodontic	872.5470	Orthodontic plastic bracket	2
-------------	----------	-----------------------------	---

Ear/Nose/Throat Panel

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

Diagnostic Equipment	874.1050	Audiometer	2
	874.1090	Auditory impedance tester	2

U.S.-EC MRA Medical Devices Annex
Table 3

Product Family	Section No	Device Name	Tier
Miscellaneous	870 1800	Withdrawal-infusion pump	2
	870 2800	Medical magnetic tape recorder	2
	None	Batteries, rechargeable, class II devices	

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

Dental Equipment	872 1720	Pulp tester	2
	872 1740	Caries detection device	2
	872 4120	Bone cutting instrument and accessories	2
	872 1365	Gas-powered jet injector	2
	872 4475	Spring-powered jet injector	2
	872 4600	Intraoral ligature and wire lock	2
	872 4810	Rotary scaler	2
	872 4850	Ultrasonic scaler	2
	872 4920	Dental electrosurgical unit and accessories	2
	872 6070	Ultraviolet activator for polymerization	2
	872 6350	Ultraviolet detector	2

Dental Material	872 3050	Amalgam alloy	2
	872 3060	Gold-based alloys and precious metal alloys for clinical use	2
	872 3200	Resin tooth bonding agent	2
	872 3250	Calcium hydroxide cavity liner	2
	872 3260	Cavity varnish	2
	872 3275	Dental cement (other than zinc oxide-eugenol)	2

**U.S.-FCC MIRA Medical Devices Annex
Table 3**

	876.5665	Water purification system for hemodialysis	2
	876.5820	Hemodialysis system and accessories	2
	876.5830	Hemodialyzer with disposable insert (kill-type)	2

Lithotripter	876.4500	Mechanical lithotripter	2
--------------	----------	-------------------------	---

Urology Equipment	876.1620	Hydromatics measurement system	2
	876.5320	Nonimplanted electrical confluence device	2
	876.5880	Isolated kidney perfusion and transport system and accessories	2

General Hospital Panel

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

Infusion Pumps and Systems	880.2420	Electronic monitor for gravity flow infusion systems	2
	880.2460	Electrically powered spinal fluid pressure monitor	2
	880.5430	Nonelectrically powered fluid injector	2
	880.5725	Infusion pump	2

Neonatal Incubators	880.5400	Neonatal incubator	2
	880.5410	Neonatal transport incubator	2
	880.5700	Neonatal phototherapy unit	2

Piston Syringes	880.5570	Hypodermic single lumen needle	1
	880.5860	Piston syringe (except anti-stick)	1

U.S.-ECC NIRA Medical Devices Annex

Table 3

	874.1120	Electronic noise generator for audiometric testing	2
	874.1325	Electrologograph	2
	874.1820	Surgical nerve stimulator/locator	2

Hearing Aids	874.3300	Hearing aid (for bone-conduction)	2
	874.3310	Hearing aid calibrator and analysis system	2
	874.3320	Group hearing aid or group auditory trainer	2
	874.3330	Master hearing aid	2

Surgical Equipment	874.4250	Ear nose and throat electric or pneumatic surgical drill	1
	874.4300	Argon laser for otology, rhinology, and laryngology	2
	874.4500	ENI microsurgical carbon dioxide laser	2

Gastroenterology/Otolaryngology Panel

Product Family	Section No	Device Name	Tier
Endoscope (including angioscopes, laparoscopes, ophthalmic endoscopes)	876.1500	Endoscope and accessories	2
	876.4300	Endoscopic electrosurgical unit and accessories	2

Gastroenterology	876.1725	Gastrointestinal motility monitoring system	1
------------------	----------	---	---

Hemodialysis	876.5600	Sorbent regenerated dialysate delivery system for hemodialysis	2
	876.5630	Peritoneal dialysis system and accessories	2

U.S.-ECF MIRA Medical Devices Annex

Table 3

882 1835	Physiological signal amplifier	2
882 1845	Physiological signal conditioner	2
882 1855	Electroencephalogram (EEG) telemetry system	2
882 5050	Biofeedback device	2
882 1240	Echoencephalograph	2
882 1100	Radiofrequency lesion generator	2
none	Electrode, spinal epidural	2
882 1405	Powered compound cranial drills, burs, rephines, and their accessories	2
882 4310	Powered simple cranial drills burs, rephines and accessories	2
882 4360	Electric cranial drill motor	2
882 4370	Pneumatic cranial drill motor	2
882 4560	Stereotaxic instrument	2
882 4725	Radiofrequency lesion probe	2
882 4845	Powered rongeur	2
882 5500	Lesion temperature monitor	2
882 1870	Evoked response electrical stimulator	2
882 1880	Evoked response mechanical stimulator	2
882 1890	Evoked response photic stimulator	2
882 1900	Evoked response auditory stimulator	2
882 1950	Tremor transducer	2

**U.S.-FCC MIRA Medical Devices Annex
Table 3**

	880 6970	Syringe needle introducer	2
--	----------	---------------------------	---

Miscellaneous	Section No	Device Name	Tier
	880 2910	Clinical electronic thermometer	2
	880 2920	Clinical mercury thermometer	2
	880 5100	AC-powered adjustable hospital bed	1
	880 5500	AC-powered patient lift	2
	880 6880	Steam Sterilizer (greater than 2 cubic feet)	2

Neurology Panel

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

?	882 1020	Rigidity analyzer	2
?	882 1610	Alpha monitor	2

Neuro-Diagnostic	882 1320	Cutaneous electrode	2
	882 1340	Nasopharyngeal electrode	2
	882 1350	Needle electrode	2
	882 1400	Electroencephalograph	2
	882 1460	Nystagmograph	2
	882 1480	Neurological endoscope	2
	882 1540	Galvanic skin response measurement device	2
	882 1550	Nerve conduction velocity measurement device	2
	882 1560	Skin potential measurement device	2
	882 1570	Powered direct-contact temperature measurement device	2
	882 1620	Intracranial pressure monitoring device	2

U.S.-EC MRA Medical Devices Annex

Table 3

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

Altm	886.3320	Eye sphere implant	2
------	----------	--------------------	---

nt Lens	886.1385	Polymethylmethacrylate (PMMA) diagnostic contact lens	2
	886.5916	Rigid gas permeable contact lens (daily wear only)	2

ostic ment	886.1120	(ophthalmic camera	1
	886.1220	Corneal electrode	1
	886.1250	Endiyscope (AC-powered)	1
	886.1360	Visual field laser instrument	1
	886.1510	Eye movement monitor	1
	886.1570	(ophthalmoscope	1
	886.1630	AC-powered photostimulator	1
	886.1640	Ophthalmic preamplifier	1
	886.1670	Ophthalmic isotope uptake probe	2
	886.1780	Retinoscope (AC-powered device)	1
	886.1850	AC-powered slitlamp biomicroscope	1
	886.1930	Tonometer and accessories	2
	886.1945	Transilluminator (AC-powered device)	1
	886.3130	Ophthalmic conformer	2
ostic/Surge quipment)	886.4670	Phacoemulsification System	2

thalm nts	886.3340	Extracocular orbital implant	2
--------------	----------	------------------------------	---

U.S.-ECMRA Medical Devices Annex
Table 3

882 5890	Transcutaneous electrical nerve stimulator for pain relief	2
----------	--	---

Obstetrics/Gynecology Panel

Product Family	Section No	Device Name	Tier
Fetal Monitoring	884 1660	Transcervical endoscope (amnioscope) and accessories	2
	884 1690	Hysteroscope and accessories (for performance standards)	2
	884 2225	(Obstetric-gynecologic ultrasonic imager	2
	884 2600	Fetal cardiac monitor	2
	884 2640	Fetal phonocardiographic monitor and accessories	2
	884 2660	Fetal ultrasonic monitor and accessories	2
	884 2675	Fetal scalp circular (spiral) electrode and applicator	1
	884 2700	Intrauterine pressure monitor and accessories	2
	884 2720	External uterine contraction monitor and accessories	2
	884 2740	Fetal monitoring system and accessories	2
	884 2960	(Obstetric ultrasonic transducer and accessories	2

Gynecological Surgery Equip	884 1720	Gynecologic laparoscope and accessories	2
	884 4160	Unipolar endoscopic coagulator-cutter and accessories	2
	884 4550	Gynecologic surgical laser	2
	884 4120	Gynecologic electrocautery and accessories	2
	884 5300	Condom	2

U.S.-EC MRA Medical Devices Annex
Table 3

Implants	888 3010	Bone fixation cerclage	2
	888 3020	Intramedullary fixation rod	2
	888 3030	Single/multiple component metallic bone fixation appliances and accessories	2
	888 3040	Smooth or threaded metallic bone fixation fastener	2
	888 3050	Spinal interlaminal fixation orthosis	2
	888 3060	Spinal intervertebral body fixation orthosis	2

Surgical Equipment	888 1240	AC-powered dynamometer	2
	888 4580	Sonic surgical instrument and accessories/attachments	2
	none	Accessories, fixation, spinal interlaminal	2
	none	Accessories, fixation, spinal intervertebral body	2
	none	Monitor, pressure, intracompartamental	1
	none	Orthosis, fixation, spinal intervertebral fusion	2
	none	Orthosis, spinal pedicle fixation	
	none	System, cement removal extraction	1

Physical Medicine Panel

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

Diagnostic Equipment	890 1225	Chonaximeter	2
	890 1375	Diagnostic electromyograph	2
	890 1385	Diagnostic electromyograph needle electrode	2
	890 1450	Powered reflex hammer	2

U.S.-EC MRA Medical Devices Annex
Table 3

Product Family	Section No	Device Name	Tier	
Surgical Equipment	886 3800	Scleral shell	2	
	880 5725	Infusion pump (performance standards)	2	
	886 3100	Ophthalmic tantalum clip	2	
	886 3300	Absorbable implant (scleral buckling method)	2	
	886 4100	Radiofrequency electro-surgical cautery apparatus	2	
	886 4115	Thermal cautery unit	2	
	886 4150	Vitreous aspiration and cutting instrument	2	
	886 4170	Cryophthalmic unit	2	
	886 4250	Ophthalmic electrolysis unit (AC-powered device)	1	
	886 4335	Operating headlamp (AC-powered device)	1	
	886 4390	Ophthalmic laser	2	
	886 4392	Nd:YAG laser for posterior capsulotomy	2	
	886 4400	Electronic metal locator	1	
	886 4440	AC-powered magnet	1	
	886 4610	Ocular pressure applicator	2	
	886 4690	Ophthalmic photocoagulator	2	
	886 4790	Ophthalmic sponge	2	
	886 5100	Ophthalmic beta radiation source	2	
		none	Ophthalmoscopes, replacement batteries, hand-held	1

U.S.-EC MRA Medical Devices Annex

Table 3

892.1650	Image-intensified fluoroscopic x-ray system	2
892.1670	Spot film device	2
892.1680	Stationary x-ray system	2
892.1710	Mammographic x-ray system	2
892.1720	Mobile x-ray system	2
892.1740	Tomographic x-ray system	1
892.1820	Pneumoencephalographic chair	2
892.1850	Radiographic film cassette	1
892.1860	Radiographic film/cassette changer	1
892.1870	Radiographic film/cassette changer programmer	2
892.1900	Automatic radiographic film processor	2
892.1980	Radiologic table	1

CT Scanner	892.1750	Computed tomography x-ray system	2
------------	----------	----------------------------------	---

Radiation Therapy	892.5050	Medical charged-particle radiation therapy system	2
	892.5300	Medical neutron radiation therapy system	2
	892.5700	Remote controlled radionuclide-appliator system	2
	892.5710	Radiation therapy beam-shaping block	2
	892.5730	Radionuclide brachytherapy source	2
	892.5750	Radionuclide radiation therapy system	2
	892.5770	Powered radiation therapy patient support assembly	2
	892.5840	Radiation therapy simulation system	2
	892.5930	Therapeutic x-ray tube housing assembly	1

U.S.-EC MRA Medical Devices Annex
Table 3

Product Family	Section No	Device Name	Tier	
Therapeutic equipment	890.1850	Diagnostic muscle stimulator	2	
	890.5850	Powered muscle stimulator	2	
Therapeutic equipment	890.5100	Immersion hydrobath	2	
	890.5110	Paraffin bath	2	
	890.5500	Infrared lamp	2	
	890.5720	Water circulating hot or cold pack	2	
	890.5740	Powered heating pad	2	
Diagnosis Panel		Diagnostic X-Ray	2	
		892.1610	Diagnostic x-ray beam-limiting device	2
		892.1620	Cine or spot fluorographic x-ray Camera	2
		892.1630	Electrostatic x-ray imaging system	2
		892.1600	Angiographic x-ray system	2
		892.1550	Ultrasonic pulsed doppler imaging system	
Ultrasound	884.2660	Fetal ultrasonic monitor and accessories	2	
	892.1540	Nonfetal ultrasonic monitor		
	892.1560	Ultrasonic pulsed echo imaging system	2	
	892.1570	Diagnostic ultrasonic transducer	2	
	892.1550	Ultrasonic pulsed doppler imaging system		
MRI	892.1000	Magnetic resonance diagnostic device	2	

U.S.-EC MRA Medical Devices Annex
Table 3

Nuclear Medicine	892.1170	Bone densitometer	2
	892.1200	Emission computed tomography system	2
	892.1310	Nuclear tomography system	1
	892.1390	Radionuclide rebreathing system	2

General/Plastic Surgery Panel

Product Family	Section No	Device Name	Tier
----------------	------------	-------------	------

Surgical Lamps	878.4630	Ultraviolet lamp for dermatologic disorders	2
	890.5500	Infrared lamp	2
	878.4580	Surgical lamp	2

Electrosurgical Cutting Equipment	878.4810	Laser surgical instrument for use in general and plastic surgery and in dermatology	2
	878.4400	Electrosurgical cutting and coagulation device and accessories	2

Miscellaneous	878.4780	Powered suction pump	2
---------------	----------	----------------------	---

**Letter of Intent between the
United States and the European Community
regarding the negotiation
of additional sectoral annexes
to the EU - U.S. Mutual Recognition Agreement**

We, the undersigned, agree that the United States and the European Community should complete their negotiations of additional sectoral annexes covering veterinary biologics and industrial fasteners. Our objective is to conclude the negotiations by the end of 1987 and to add these annexes to the EU - U.S. Agreement on Mutual Recognition.


For the United States of America


For the European Community


**MEMORANDUM OF UNDERSTANDING REGARDING THE JOINT COMMITTEE UNDER THE
FRAMEWORK AGREEMENT ON MUTUAL RECOGNITION BETWEEN THE UNITED STATES OF
AMERICA AND THE EUROPEAN COMMUNITY**


The United States and the European Community have negotiated an Agreement on Mutual Recognition (the "Agreement"), consisting of an umbrella agreement and several sectoral annexes. Products covered in the Sectoral Annex for Pharmaceutical Good Manufacturing Practices ("GMPs") and the Sectoral Annex on Medical Devices are regulated by the United States Food and Drug Administration ("FDA").

The umbrella agreement establishes a Joint Committee responsible for the effective functioning of the Agreement as a whole, and the sectoral annexes on pharmaceutical GMPs and medical devices establish separate Joint Sectoral Committees responsible for the operation of the respective sectoral annexes. Under the Agreement, issues discussed in the Joint Sectoral Committees regarding, among other things, equivalence determinations of authorities or conformity assessment bodies, may be referred to the Joint Committee.

In recognition of the relationship between the Agreement and FDA's core domestic statutory and regulatory responsibilities relating to protection of health and safety under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and related statutes, execution of which is committed to FDA, and in light of the United States Trade Representative's (USTR) role under section 141 of the Trade Act of 1974 and Reorganization Plan #3 of 1979, FDA and USTR set forth in this Memorandum of Understanding ("MOU") the understandings and procedures which will guide their cooperative execution of the Joint Committee provisions of the Agreement.

Upon establishment of the Joint Committee pursuant to Article 14 of the Agreement, USTR shall notify FDA of matters to be considered by the Joint Committee. Subject to arrangements with other agencies covered by the Agreement, USTR normally shall speak for and vote on behalf of the United States in the Joint Committee. A representative of FDA shall speak for and vote on behalf of the United States on any matter pertaining to FDA's statutory or regulatory authority. The representative of FDA shall also represent the USG on such matters in any other committees or bodies with similar functions established under the Agreement or its annexes.


Susan G. Esserman
General Counsel
United States Trade Representative


Michael A. Friedman, M.D.
Lead Deputy Commissioner,
United States Food and Drug Administration

Date: April 16, 1998

Date: 5/198

